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Chapter 8: Implications of secondary findings for clinical contexts 
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Abstract 
Deciding how best to deal with unsought diagnostic or prognostic information provided 
by NGS techniques is one of the key issues for viable translation of genomics into 




issue of how to deal with ‘additional’ genomic findings in adult care, but it is not the 
only model. Examples of clinical and translational genomics from the USA, UK, 
Australia, Germany, France, Japan, Singapore, Estonia and the Canadian province of 
Quebec illustrate a range of approaches to secondary or additional findings. Other 
cases, including testing in paediatric and prenatal populations, testing for lifestyle or 
wellness applications, and neonatal screening illustrate the different clinical contexts 
in which secondary or additional findings must be considered. In each case, practical, 
organisational, economic, legal and ethical aspects of dealing with secondary findings 
must be taken into account when deciding how best to proceed. 
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 Over the past 5 years several countries have initiated research projects that will 
set the stage for rollout of next generation genome sequencing (NGS) in the clinic. For 
example, the 100,000 Genomes Project in the UK (announced in 2013), the Precision 
Medicine Initiative in the USA (announced in 2015), and the Australian Genomics 
Health Alliance (AGHA) (announced in 2015) all examine the all examine the 
opportunities for introducing genomics into routine patient care. Implementation, 
whether of whole genome sequencing (WGS), whole exome sequencing (WES) or 
multiple panel tests, will not occur overnight; there will be a continuing need to gather 
data at a population level to progress our understanding of genomics, necessarily 
bringing clinical care into close contact with research, as research participants are 
recruited through the clinic, and research findings are relevant for immediate patient 
care. This blurring of lines between research and clinical care raises distinct ethical 
challenges, as the limits of our understanding of the implications of genetic variation 
are quickly reached. Developing clear policies to manage this potential friction is 
crucial to support researchers and clinicians working in this area, managing the 
findings from genomic sequencing and supporting individuals, as both patients and 
research participants, in their understanding of the implications of this data. 
 
 The results arising from genomic sequencing are often separated into two 
distinct categories, 1) health related findings – or findings that are ‘pertinent’ to the 
question intended to be answered by sequencing, and 2) variants that are not 
immediately relevant to the question, described as incidental, accidental, secondary, 
unsolicited, unexpected, unrelated, non-pertinent, ancillary, additional. A third 
category could perhaps be 3) variants of unknown significance (VUS), as, given their 
significance has not yet been determined, it is difficult to tell whether they might 
eventually be pertinent or not. VUS are usually included in category 2, however, and 
treated as an incidental, or secondary finding (the term used herein). The 
categorisation of findings is usually drawn along the lines of pertinence, rather than 
distinguishing between somatic or germline findings, as this is determined by the initial 
question. 
 
The likelihood of secondary findings may differ in clinical care and research settings, 
given that genomic sequencing within the clinic is more usually initiated for diagnostic 
purposes, which may give rise to a more defined question being asked, and a clearer 




is still significant risk that in these explorations, other information will be unearthed that 
could be relevant to the patient. Understanding how to broach these occurrences in 
both the clinic and research are is vital, if the information has health implications. Given 
the clear need for guidance for healthcare practitioners and researchers working in 
this area, the first challenge is to define secondary findings. 
  
The American College of Medical Genetics and Genomics (ACMG) define ‘incidental 
or secondary findings’ as: “the results of a deliberate search for pathogenic or likely 
pathogenic alterations in genes that are not apparently relevant to a diagnostic 
indication for which the sequencing test was ordered.” In the UK, a report 
commissioned by the Medical Research Council (MRC) and Wellcome Trust (WT) 
(referred to herein as the ‘MRC/WT report’) defines them as a finding ‘which is 
discovered in the course of conducting research, but is beyond the aims of the study’. 
Interestingly, the ACMG definition alludes to a deliberate search for such findings, 
while the WT/MRC report, in its more general description, would relate to findings both 





 As the previous chapters in this volume describe, secondary findings are 
intensely debated within the genomics community, and there is uncertainty about how 
best to manage them, whether they should be fed back to research participants, and 
if so, in what circumstance. In the clinic, opinion is divided on how best to proceed and 
what information the patient should receive. Secondary findings are not a challenge 
solely contained within genomics; in any medical specialism there might be risk of 
finding something about the patient’s health that is not related to the initial question, 
for example the startling frequency with which cancer diagnoses are made in the 
course of Accident and Emergency department care, or tumours being detected in 
imaging scans that were requested for something completely different. The difference 
with genomics is the relative infancy of the field, the scale of uncertainty about what 
different findings mean, and the implications they have for a patient’s health (and that 
of their family). The timescale of influence is also relevant – often secondary findings 
in other specialisms have immediate consequences for a patient, while in genomics 
the information could be related to a risk of disease where symptoms could lie decades 
into the future or may never materialise. 
 
 As focus on genomics continues, and more countries conduct population-level 
research projects to set the foundations for rollout of sequencing in clinical care, the 
issue of secondary findings is increasing in prominence. Researchers are universally 
encouraged to consider their policies on feedback of results, and are looking to their 
professional bodies for guidance. In response to the clear need for a position on 
secondary findings to support healthcare practitioners the ACMG ignited discussion 
on this topic with their announcement in March 2013 of a list of 57 genes deemed 
medically actionable. These were mutations that could lead to severe outcomes, 
including inherited cancers, inherited cardiac diseases, connective tissue diseases 
affecting the cardiovascular system, familial hypercholesterolemia, and malignant 
hyperthermia susceptibility. The ACMG recommended that known pathogenic (or in 
some cases expected pathogenic) variants discovered in any of these genes should 





 The international community were largely critical of the two elements of this 
recommendation, one, that these variants should be actively sought, and two, that they 
should be fed back to the individual whether they wanted to receive them or not. For 
many, this undermined the ethical concept that a patient had a ‘right not to know’, while 
creating significant implications for project resource. The European Society of Human 
Genetics (ESHG) took a much narrower approach, advising that whole-genome 
sequencing be restricted to regions of the genome that were most likely relevant to the 
patient’s potential diagnosis, with wider testing needing specific justification. Actively 
searching for additional findings would therefore go against this premise. In recognition 
that unsolicited findings would occasionally occur, the ESHG made clear that the 
patient’s right not to know was important, although in instances where the patient is 
not in a position to fully understand the implications of not knowing a result, the 
physician may still have a moral duty to inform relatives. The general advice was to 
adopt a cautious approach.  
 
In response to this criticism, the ACMG amended their recommendations in 2016 
stating that ‘Adherence to these recommendations is completely voluntary and does 
not necessarily assure a successful medical outcome.’ The approach taken by the 
MRC/WT report was more to guide researchers in how to think about the problem, 
rather than prescribing a solution, acknowledging that policy would be highly project 
dependent, further research was needed to fully access risks and benefits to patients, 
and concluding that above all projects needed to think about secondary findings and 
draft a clear policy in advance.  
 
 Several high-profile examples from the UK demonstrate the difficulty 
encountered when pre-emptively designing policy. The UK Biobank recruited 500,000 
participants aged between 40-69 (2006-2010) to gather health data and samples for 
future research. The policy upfront was that participants would not receive any results, 
as stated in the consent form: ‘I understand that none of my results will be given to me 
(except for some measurements during this visit)’. When UK Biobank introduced an 
imaging project, this policy changed, to allow for the possibility that secondary findings 
might be returned, specifically relating to the findings from scans. While this is not a 
genomics example, it demonstrates the difficulty different projects may have in 
anticipating issues ahead of time, and balancing practical measures with the concerns 
of personnel involved in analysing results, who might feel obliged to feedback 
information. Part of the challenge is that patients have mixed views of how to broach 
secondary findings. Patients involved in focus groups that fed into the MRC/WT report 
offered a broad spectrum of opinion, ranging from the supportive: “You’ve got the 
choice then to respond...and for your family to be aware also, if maybe there’s a 
possibility it's hereditary, or there’s maybe a female carrier or a male carrier with an 
illness.” [Focus group participant, Cardiff] to the doubtful: “It might create unnecessary 
worry which potentially could lead on to psychosomatic illnesses. You think you’re ill, 
you’re going to be ill.” [Focus group participant, Cardiff]. 
 
 A 2016 paper1 questioned different stakeholders about feeding back research 
findings to participants that may not be related to primary project aims. This cross-
sectional survey gathered views from 6944 individuals (75 countries), including 
members of the public (4961), genetic health professionals (533), non-genetic health 




(98%) considered treatability of the condition/disease to be paramount, but most did 
not expect researchers to actively search for secondary findings within a research 
setting. The study demonstrated that on many issues, the genetic health professionals 
held more conservative views than other stakeholders, which might suggest the need 
for further exploration of this area to better understand the disconnect between the 
views of the professionals, who arguably understand the implications of the data more 
clearly, and those of the patient. 
 
 The differences of opinion across the genomics community extend beyond just 
the policy approach to feeding back results. One of the major challenges within this 
complex discussion lies with the science itself. Clinical actionability is put forth as a 
useful criterion for feeding back results or not, and understandably so – if there is 
something that could immediately be done to improve the health of the patient, 
rationally, and indeed ethically, this should be promoted. Defining clinical actionability, 
however, is difficult. There is disagreement amongst genomics experts about which 
variants might be acted upon, and how, and crucially what this might mean for 
immediate patient care. Furthermore, clinical actionability suggests relevance to the 
immediate patient, however some of the results that could have major significance are 
related not to the health of the patient, but instead to future generations, relating to the 
carrier status of individuals, which may have implications for future reproductive 
decisions. Paediatric care similarly raises further challenges, given the timeframes for 
actionability – should variants relating to adult-onset conditions be disclosed to 
children (via their parents), and what implications might that have for their childhood 
and future autonomy? 
 
 This level of disagreement across different aspects of secondary findings is the 
reason for the need for careful consideration of policies, further discussion with 
patients, and better understanding of the implications of this information. The language 
used to describe this group of findings may influence how they are addressed by the 
community and received by patients. As alluded to above, ‘incidental’ is commonly 
used, and clearly refers to findings that were not immediately relevant to the question 
in hand, however the term has received criticism from patients, for the connotation of 
non-importance. Given these findings could refer to risk of life-threatening disease, 
including cancer and heart disease, they may be of huge significance to the patient, 
regardless of the initial clinical question. 2 
 
 It is helpful to draw a distinction between findings that are not-pertinent to the 
primary clinical purpose for which NGS analysis is being carried out, but which are 
actively looked for, and those that are accidentally discovered, as these two groupings 
would require different procedures from the clinical teams involved. It would be 
relatively straightforward to have a policy that stipulates that findings will not be fed 
back, and thus states that the clinical team will not actively look for these variants. 
However if a variant that could have clinically significance is genuinely unexpectedly 
uncovered, it may then fall to the conscience of the bioinformatician about whether this 
should be fed back. Anecdotally, this is said to happen reasonably often, where a 
researcher has gone against an explicit policy because a result could have such 
dramatic and immediate consequence for a patient. By encouraging teams to devise 
policies in advance, it is hoped this scenario could be avoided, and the policy could be 





 This chapter will explore initial experiences in different nation states to 
understand how return of secondary and incidental findings in clinical contexts has 
played out so far, and what can be learnt from these approaches.  
 
Table 1.0: Definitions provided in each case study 
Country Term Definition 
USA Secondary findings Actively looked for, 
clinically relevant 
UK Incidental findings Secondary findings – that 
are actively sought after 
but are not related to the 
condition in question 
Australia Incidental / secondary Result from analysis of the 
data / interrogation of 
genes that are not 
indicated by the patient’s 
clinical presentation 
Germany Additional findings Findings unrelated to the 
initial investigation/ 
question, but relevant for 
the health and/or 
reproductive plans of the 
person and/ or relatives 
France Secondary or incidental Will not hunt for specific 
variants; would only return 
actionable results 
Canada Secondary findings 
Incidental findings 
 
Singapore Secondary findings or incidental 
findings (of potential health or 
reproductive importance) 
Incidental findings are 
broadly defined in the law 
to include what are known 
internationally as 
‘secondary findings’ 
Estonia Incidental findings (or secondary) Clinically significant 
unrelated to the indication 
of testing 
Japan Incidental/secondary findings Non primary results; 
germline variants of 
inherited diseases that 
could be found during 
analysis of cancer tissues 
and blood samples using 
gene panels 
 
2) International approaches to genomics in clinical care and translational 
medicine 
 Genomics is a global phenomenon, although it is not developing at the same 
pace or in the same way in all territories and jurisdictions. This section presents a 
snapshot of the way genomics is being implemented in clinical practice in a range of 




secondary or additional findings is being dealt with in different countries with different 
healthcare systems and different governance regimes. Since genomics is not yet a 
routine part of clinical care for most patients in most states, these country profiles also 
review current translational genomics efforts and, where relevant, the influence of 
research governance on the process of the translation of genomic sequencing into the 
clinic. 
 
2.1 United States 
 Medical practices, such as how to manage secondary findings, in the US are 
most often determined by the standard of care or the type of care that is expected from 
a minimally competent physician in the same field, with similar experience, and under 
similar circumstances.3 The standard of care is often shaped by the way physicians 
typically manage a particular situation in the clinic. However, many states also require 
that clinicians do not just do what others ordinarily do, but that their actions are also 
those of a reasonably prudent clinician.3 A standard of care may also be influenced by 
hospital policies, state or federal regulations, and statements from influential 
professional groups. When novel technologies, like genomic testing, enter the clinical 
context, the standard of care may be unclear because it takes time for a standard to 
develop.  
 
 When it comes to managing secondary findings in the clinical setting, there are 
no US state or federal regulations that directly address this issue. Thus, their 
management depends mainly on the standard of care that develops among clinicians 
handling secondary findings. In 2013, The American College of Medical Genetics and 
Genomics (ACMG) published recommendations regarding how to manage some 
aspects of secondary findings in the clinical setting. The ACMG recommended that 
“whenever clinical sequencing is ordered, the ordering clinician should discuss with 
the patient the possibility of [secondary] findings and that laboratories should seek and 
report [57 secondary findings]…described in [these recommendations] without 
reference to patient preferences.”4 These recommendations were influential in the US 
for various reasons, including the standing of the ACMG as a professional 
organization, and that they published at a time in which there was little guidance about 
how to manage these findings. Thus, these recommendations helped fill a gap in the 
standard of care. As described in more detail below, medical professionals and 
institutions in the US are, to a large extent, following ACMG’s current 
recommendations regarding secondary findings. 
 
 After the ACMG published its original recommendations, there was significant 
backlash because many interpreted the ACMG recommendation not to ask patients 
whether they want secondary findings analyzed, as a violation of the tradition and legal 
obligation of respect for patient autonomy in the US. 5,6 The ACMG responded by 
modifying their recommendations to offer patients the opportunity to opt out of the 
analysis of secondary findings.7 More recently, the ACMG published an updated list 
of the now 59 “medically actionable genes” that the organization recommends should 
be analysed as secondary targets, whenever clinical sequencing is performed.8 The 
Secondary Findings Maintenance Group of the ACMG will periodically curate and 
update their list (Available at: www.acmg.net) of medically actionable genes 






 Studies have examined the degree to which clinical sequencing laboratories in 
the US are following the ACMG guidelines. Fowler and colleagues found that 94% of 
consent forms examined from these clinical laboratories contained language that 
stipulates whether the laboratory will examine and report findings regarding the ACMG 
list of 59 secondary target genes.9 Approximately 80% of clinical laboratories offered 
patients the opportunity to opt out or opt in of the report of some or all the 59 ACMG 
genes. This suggests that the ACMG guidelines have been influential in practice and 
that, based on their consent forms, clinical genomics laboratories in the US are 
following the ACMG recommendations regarding secondary findings. As the practice 
of offering the analysis of ACMG-recommended secondary targets in the clinical 
setting becomes more prevalent, a more concrete standard of practice and standard 
of care emerges for clinical sequencing laboratories and clinicians, respectively.  
 
 The ACMG list of medically actionable genes is likely the most influential and 
widely used in the US when it comes to offering secondary findings. However, it is 
important to note that there is no clear consensus regarding what constitutes a 
medically actionable gene.  Geisinger Health System’s My Code Community Health 
Initiative encourages patients to submit samples for genomic sequencing and it 
analyses and reports back findings from 77 medically actionable genes associated 
with 25 conditions.10,11 Notably, My Code is a screening program and, therefore, 
strictly speaking, these would not be considered secondary findings because 
examining these medically actionable genes is the primary goal of this program. To 
further evidence the differences in what is considered a medically actionable gene that 
should be offered to individuals, in the research context, there are groups that have 
identified up to 168 medically actionable genes.12 
  
 The way certain issues are managed in a research context often influences how 
they are later managed in clinical practice. Thus, it will be important to be attentive to 
how projects such as the All of Us Research Program manage secondary findings. All 
of Us plans to recruit 1 million individuals in the US and to offer to return medically 
actionable findings, but the program has not determined which findings it will analyse 
and make available to participants, what kind of opt out alternatives, if any, or how it 
will return findings.13,14 Furthermore, the US National Academies of Science, 
Engineering, and Medicine (NASEM) recently published a report in which it 
recommends that researchers carefully consider returning findings, particularly 
medically actionable findings, to individual research participants.15 Thus, in the US, 
the trend toward offering to return medically actionable findings as secondary or 
primary targets is on the rise in both the research and clinical settings. On the other 
hand, there is much more uncertainty about what is considered a medically actionable 
gene, what criteria are used to determine this, and how these criteria should be 
applied. Since secondary findings offered in clinical care are generally medically 
actionable genes, it will be important to follow how this debate progresses and for 
groups that offer secondary findings, to be transparent about their selection criteria.  
 
2.2 United Kingdom 
The UK’s major national genomic sequencing programme is the 100,000 
Genomes project. The project was launched in 2013 by then Prime Minister David 
Cameron as a way of operationalising recommendations made in a previous UK 
government white paper on genetics.16,17 Genomics England, a wholly owned 




project, which began recruiting through Genomic Medicine Centres located in the UK’s 
National Health Service (NHS) in 2015. This heralded a concerted focus on genomic 
medicine within the NHS, seeking to exploit existing academic expertise and establish 
the UK at the forefront of the field, as well as to boost the country’s commercial science 
industry. The project aimed to sequence 100,000 genomes by WGS from around 
70,000 NHS patients and their families with a rare disease or adults who have cancer, 
as well as the less widely discussed or transparent infectious disease arm led by Public 
Health England. 
 
 Rare disease was chosen in an attempt to reduce the diagnostic odyssey that 
many patients with rare disease experience, and cancer was picked to stimulate the 
development of patient-specific medications by members of the Genetics Expert 
Network for Enterprises (GENE) consortium. This group of commercial partners have 
contributed financially towards the project and will have access to patient data to 
facilitate drug development. The project is described as ‘clinical transformation’ and 
the varied components situate it somewhere between research and routine clinical 
practice. Whilst this has the benefit of catalysing use of this technology in the Health 
Service, it also poses challenges in encouraging clinician and patient uptake.   
 
Primary findings are fed back to patients through standard NHS pathways and 
were initially based on a gene-panel (via PanelApp, a crowd-sourced tool allowing 
curation and review of condition-specific gene panels) approach, with pathogenic 
variants in known disease-causing genes reported. Where this is not successful, the 
relevant Genomics England Clinical Interpretation Partnership (GeCIP) will be tasked 
with finding an answer to the clinical question. GeCIPs provide access to sequence 
data for over 2,500 academic and public-sector researchers and clinicians organised 
around particular disease categories or cross-cutting topics such as functional 
genomics and machine learning).  
 
The project literature18 makes no mention of incidental findings, however it does 
explain the meaning of secondary findings (referred to in the project as additional 
findings) defined as findings that are actively sought but not related to the condition in 
question. These are available on an opt-in basis and relate to a small list of serious 
and clinically actionable genes containing variants responsible for inherited cancer 
syndromes or cardiovascular disease.  This list is not static however and the patient 
consents to receive information on all the conditions and genes on the list at the time 
of reporting, not those present when consenting. In children, this will be limited to 
information concerning childhood onset conditions. Carrier status will be reported on 
a small list of conditions (currently only cystic fibrosis) providing both members of a 
couple are recruited into the study and both consent to receiving this additional 
information. X-linked carrier status may be returned if appropriate. These secondary 
findings are returned to patients separately and at a later date compared to the primary 
clinical findings relating to their reason for testing.  
 
Outside the 100,000 Genomes Project, within the NHS there are no other 
examples of secondary findings being routinely sought or returned. Policies 
concerning truly incidental findings are often ad hoc and vary by laboratory. In this 




findings could be seen to provide clarification throughout the NHS but the lack of any 
guidance regarding incidental findings still leaves laboratories, clinicians and patients 
unsure as to what constitutes best practice. As genomic medicine becomes more 
mainstream, a clinician’s obligation to disclose genomic findings becomes 
complicated. There is no legislation at the current time surrounding the duties of care 
in genomic sequencing, and no legal duty to look for secondary findings or return 
incidental findings.19 The onus therefore reverts to a duty of care or candour and what 
is deemed (probably retrospectively if challenged) to be the appropriate standard of 
care. Both the ESGH20 and the Public Health Genomics (PHG) Foundation, a UK 
based health policy think-tank in genomics21 oppose the ACMG position on secondary 
findings and advocate a targeted approach to sequencing.  
 
As well as the difficulties surrounding legislation and best clinical practice, there 
are also concerns regarding clinical utility of secondary findings in a population 
context. The majority of knowledge regarding the pathogenicity of variants is derived 
from the traditional Clinical Genetics phenotype-to-genotype model where patients 
with symptoms or a family history of a condition present to the health service. Variants 
found in these patients can be interpreted in the context of the clinical picture of the 
proband or their affected family members. This is not the case in a secondary findings 
context. Patients will usually have no symptoms relating to the variants identified and 
may have no family history. Population genomic databases such as ExAC and 
gnomAD have demonstrated that it is possible to carry a pathogenic variant and not 
exhibit serious disease symptoms, leading to reclassification of certain variants. This 
could be due to incomplete or age-dependent penetrance, or other genetic co-
factors.22 Without further data and knowledge of the effects of secondary findings in 
the wider UK population, it is difficult to predict what the pathogenicity of variants are 
even in well-characterised disease genes.23 
 
Studies have shown that the disease burden of carrying a ‘pathogenic’ variant 
in an asymptomatic person in unclear but could be significantly lower than previously 
suspected. 23,24 This could lead to over-diagnosis of future disease and those patients 
may endure unnecessary stress and worry dealing with variants they cannot 
comprehend, as well as additional and potential risky confirmatory tests or prophylactic 
treatments they may choose to undertake.6  For this reason, a number of 
commentators, including a Genomic Medicine Multidisciplinary Team (GM-
MDT) responsible for local review of genomic sequence data in Oxford have 
advocated a ‘not pathogenic until proven otherwise’ approach, where only variants 
definitively shown to be pathogenic should be fed back as secondary findings.25 
However, there is then a risk of a two-tier variant classification for primary and 
secondary findings which could lead to confusion for both patients and interpreting 
clinicians.  
 
In summary, within the UK, the 100,000 Genomes Project is leading the way 
regarding clinical secondary findings in genomics and is likely to form a template for 
the ongoing NHS genomic medicine service. The political and medical importance of 
the project was reinforced in 2016 as the Chief Medical Officer chose to base her 
annual report on “Generation Genome”. The report highlighted the potential of 
genomic medicine to aid the NHS in areas such as diagnostics, personalised 
medicine, drug discovery and disease prevention.26 More recently, in spring 2018, the 




the NHS, realising the 2012 vision of transforming patient care through genetic and 
genomic services.27 Seven national genomic hubs will provide genome testing for 
various conditions and are now planned to be operational by January 2019.28 
However, more population level data associated with clinical outcomes (including from 
the 100,00 genomes project itself) will be needed to help appropriately interpret 
genomic variants and guide counselling to patients.  
 
2.3 Australia 
 In Australia, genomic sequencing tests are making a rapid transition from 
research to clinical practice. Australia’s component states and territories are 
responsible for the delivery of public hospital services, which include genetic services. 
There is therefore a risk of divergent clinical practices arising in potentially contentious 
areas such as the return of secondary or incidental findings. National bodies, however, 
have not yet set policy which directly addresses secondary results. For the purposes 
of this section, the term “secondary findings’’ is used to mean result from an analysis 
of the data/interrogation of genes that are not indicated by the patient’s clinical 
presentation (e.g. ACMG list genes in a patient with intellectual disability). 
 
 In 2015, the Australian National Health and Medical Research Council 
produced a ‘decision tree’ for the management of findings from research and health 
care within their Principles for the translation of -omics based tests from discovery to 
health care.29 Although recognising the potential for the identification and/or return of 
incidental and secondary findings, it simply advises following policy, patient 
preferences or national genomics guidelines (which do not yet exist on this issue).  
The Human Genetics Society of Australasia have produced a commentary on the 
ACMG guidelines30, stating that they represent a significant change from previously 
accepted guidelines on genetic testing and advising exercising caution in adoption.  
The Royal College of Pathologists of Australasia recommends targeted analysis, i.e. 
only analysing those genes relevant to the clinical indication for testing, noting that it 
is a pragmatic approach to minimise the ethical dilemmas arising from “incidental” 
findings.31 They also observe that, while debate and guideline development are in 
progress, different practices are emerging and each laboratory should provide a clear 
verbal and written communication of their policy.   
 
 In the Australian State of Victoria, the Melbourne Genomics Health Alliance was 
formed to integrate genomics into clinical practice across its member organisations.32 
These currently encompasses five hospitals, each with a genetic service, and five 
accredited laboratory services.  Initial consultations in 2013-14 indicated that 
secondary findings were a concern to some medical specialists.33 Stakeholder 
interviews conducted in 2015 showed that no consensus on secondary findings had 
emerged.33 The Community Advisory Group, clinical and laboratory stakeholders, and 
ethics committees supported an approach whereby analysis and interpretation is 
restricted to the genes indicated by the patient’s clinical presentation.  Analysis and 
interpretation of the ACMG genes are deliberately blocked, unless a specific gene is 
clinically indicated.   
 
 The rationale for excluding the ACMG gene list during the early implementation 
of genomics in practice was as follows:  Firstly, patients needed only consider the 
implications of their diagnostic test in pre-test counselling.  Secondly, clinicians who 




additional burden of discussing secondary findings prior to testing or managing any 
results afterwards.  In addition, laboratory workload was minimised and prioritised 
results of most immediate clinical use.   
 
 Publicly funded health care systems, such as Australia’s, are constrained.  Any 
increased use of resources – be they personnel time, infrastructure or consumables – 
have an opportunity cost. That is, those resources are not then available to provide 
another health service.  The ratio of the cost of health intervention to the benefit it 
produces must be shown to warrant the allocation of resources.  In Australia, national 
government reimbursement of new medical services and tests is largely dependent on 
a health technology assessment of this nature.34 American laboratories report that the 
ACMG guidance has meant that they have had to incorporate a new workflow35, but 
the costs and the benefits of testing have not yet been measured.  Australian evidence 
of both the costs and benefits is also lacking.   
 
 The Melbourne Genomics Health Alliance is now assessing a sequential model 
for offering patients secondary findings.36 Adults are offered a secondary findings 
analysis after the clinically indicated WE/GS results are available.  This is possible 
since the current guidelines suggest that genomic data arising from clinical testing 
should be stored31 meaning the data is available for reanalysis.  The Melbourne 
Genomics Health Alliance refers to these as ‘additional findings’, in concordance with 
patient preferences2 and to emphasise that it is ‘extra’ information arising from an 
additional analysis.  Testing is offered with pre- and post-test counselling. If the patient 
accepts, their stored genomic data is reanalysed for genes predictive of actionable 
adult-onset conditions. These genes all have defined clinical management pathways 
which are publicly funded in the Victorian health system.  Evaluation of this model is 
designed to inform health technology assessment and clinical service delivery 
decisions by capturing costs and assessing the process of service provision.36 This 
evaluation does not provide the information needed to determine if secondary findings 
should be available but is essential to inform decisions regarding how they can be 
offered and returned. 
 
 There are at least two anticipated advantages of a sequential model for 
secondary findings. Firstly, if people wish to learn secondary findings, they can choose 
the point in their life that best suits them. This may not be when they are seeking a 
diagnosis or making clinical management decisions.  Secondly, they have an 
opportunity to fully consider the implications of the secondary findings before 
proceeding.  Genetic counsellors and patients have reported that scant attention is 
paid to these when diagnostic testing and secondary findings are offered concurrently. 
37,38  
 
 The concurrent model of testing – whereby consent for both diagnostic testing 
and secondary findings are sought at the same time – is also being tested with a cohort 
of infants diagnosed with congenital deafness through the Victorian Infant Hearing 
Screening program.  Parents who consent to genomic sequencing of their infant are 
offered three alternatives: to restrict analysis to genes known to cause deafness; to 
also include analysis of genes known to cause childhood onset conditions with 
treatment pathways; or to include all genes known to cause childhood onset 
conditions.  Parents’ choice and experience are being captured through evaluation 




  An international study reporting laboratory practices found that none of the 
participating Australasian laboratories in any state searched for secondary findings at 
that time.40 There were, however, some differences in practice relating to the return of 
unsolicited findings; that is potentially disease-causing variants inadvertently identified 
in genes unrelated to the original rationale for testing. In May 2018, the Australian 
Government announced a AUD$500M investment over ten years in genomics 
research to set a robust foundation for genomic health care.  With funding from the 
National Health and Medical Research Council, a collaboration of more than 80 
organisations,  Australian Genomics, is conducting a program of work to develop tools 
(such as a national clinical consent form) and provide evidence for the equitable, 
effective and sustainable delivery of genomic medicine in healthcare.  Australian 
Genomics aims to harmonise approaches nationally by strengthening networks 
between clinicians, researchers and diagnostic geneticists from its participating 
organisations across all Australian States.41   At the level of government, national 
consistency will be achieved through implementation of the National Health Genomics 
Policy Framework by the state and federal jurisdictions.42 
 
2.4 Germany 
The landscape of genomics in Germany is rather heterogeneous. Whereas panel 
sequencing is part of routine clinical practice, WGS and WES do not yet form part of 
routine clinical diagnostics and are mainly employed in basic and translational 
research settings.  This is reflected by the status of WGS and WES within the system 
of reimbursement for clinical care services in German public health care. The public 
reimbursement system does not encompass WGS and WES as reimbursable 
standard health care diagnostics. NGS-panels up to 25 kb or designated as basic 
diagnostics are covered by the statutory health insurance system. Reimbursement of 
larger panels and extended diagnostics using WGS or WES is available only within 
special programs; in general, reimbursement has to be applied for individually through 
statutory health insurance.43 Clinical use of WGS and WES is usually driven by 
research oriented interests and initiatives, or used within clinical contexts which are 
traditionally close to research such as paediatric genetics (e.g. diagnosis of rare or 
unknown developmental diseases). A growing number of interdisciplinary molecular 
tumour boards are also being established in academic oncology centres to apply NGS 
analyses to the diagnosis of certain cancer patients.44 
 
There is no national program to promote genomic research and its implementation into 
the clinic comparable to the UK 100 000 Genomes Project. However, several smaller 
public research programs fund genomic approaches. One example is the e:Med 
program sponsored by German Ministry of Education and Research (BMBF), which 
aims to establish systems medicine in Germany. Another, the German Medical 
Informatics Initiative (MII), aims to establish medical data integration centres to allow 
for integrated analyses and research uses of clinical data from all German university 
hospitals, including genetic/genomic data from routine care and, ultimately, genomic 
data from research contexts as well.45 One of the institutional hubs in Germany for the 
paradigmatic ‘‘omics’ field of cancer research is Heidelberg, with three institutions 
(German Cancer Research Centre, the European Molecular Biology Laboratory and 
the University Hospital) engaging in joint genomic activities. It is no coincidence that 
one of the most detailed guidelines for genomic sequencing was issued by the 





The German Gene Diagnostic Act (Gendiagnostikgesetz, 2009) does not explicitly 
mention or address secondary or incidental findings. However, the parliament’s official 
motivation for the act refers to “unexpected results” from genetic analyses 
(“unerwartete Untersuchungsergebnisse” 27) and to “excess (or surplus) information” 
(“Überschussinformationen”).46 Such unexpected results are considered to result from 
methods that generate information on genetic characteristics of patients beyond the 
medical or clinical scope of the genetic analysis. The official motivation document of 
the act states that during the consent process patients have to be informed about the 
possibility of “excess information” and “unexpected results” and should be able to 
decide whether they want to have ‘unexpected’ results returned to them or not. The 
act itself provides that the return of any genetic results to patients must be performed 
by physicians. The act thus effectively determines legal provisions within the clinical 
context that apply to incidental findings and which would also apply to secondary 
findings. It does not apply to the research context, leaving many unresolved questions 
concerning incidental and secondary findings in research genomics.   
 
Several prominent German scientific organisations have published statements or 
recommendations concerning genetics and genomics. In 2013, the Berlin-
Brandenburgische Akademie der Wissenschaften issued an “ad hoc statement on the 
consequences of new sequencing technologies for genetics in the clinic”.47 The 
statement uses the term “excess information” (“Überschussinformation”) but does not 
discuss secondary findings or incidental findings. The same year, the German Ethics 
Council (DER) published a statement on “the future of genetic diagnostics”.48 As 
indicated by the title, the statement mainly refers to the clinical context. The DER 
statement does not explicitly refer to secondary or incidental findings, but refers to 
“excess information” and “additional result” (“Nebenbefund”, literally “beside result”). 
The statement defines “excess information” as information, generated through genetic 
analyses, which is not needed for answering the clinical question of the analysis or 
which occurs unexpectedly or undesirably. “Additional results” are defined as results 
generated from “excess information” which are beyond the medical goal of a directed 
genetic analysis. As to practical handling, the statement mainly states that excess 
information and additional findings are likely to increase in the future and that pertinent 
ethical and legal challenges, relating for instance to the information and consent 
process, need to be addressed especially with respect to WGS and WES in the 
research context.  
  
The German Society of Human Genetics (GfH) issued a “statement on genetic 
additional findings in diagnostics and research” in 2013.49 As indicated by the title, the 
statement focuses on “additional findings” and chooses a differentiated approach, 
considering the clinical context and research context separately. The authors declare 
the English term “incidental finding” does not completely suit their conceptual needs 
and they prefer the German term “Zusatzbefund” (which might be best traduced as 
“additional finding”). They define “additional findings” as findings unrelated to the initial 
investigation or question, but which nonetheless have relevance for the health and/or 
reproductive plans of the person herself and/or her relatives. The term “secondary 
finding” is not mentioned.  
 
In the clinical context, the authors state (in accordance with paragraph 9 of the Gene 
Diagnostic Acts) that consent must include information on the possible occurrence of 




patient. Data security, the patient´s right not to know, and the protection of people 
incapable of giving informed consent must also be considered. In the research context, 
by contrast, the report finds neither a duty to establish a diagnosis nor an obligation to 
report additional findings. If additional findings are likely to occur, the possibility and 
handling of additional findings must be clearly addressed during the consent process. 
If there is an agreement with the patient/participant to return additional findings, it is 
necessary to define a time period in which the information will be given.  
 
Where patients and participants agree to the return of incidental findings, it is 
necessary to clarify which kind of results will be reported. Results have to be reliable, 
scientifically validated and are categorized as follows:  
1. Genetic characteristics bearing a significant risk to develop a specific disease, 
which can be treated effectively or preventively.  
2. Genetic characteristics bearing a significant risk to develop a specific disease, 
which cannot currently be treated. 
3. Genetic characteristics bearing a slightly modified risk to develop a certain 
disease. 
4. Genetic characteristics bearing no health related risk for the patient/participant 
– but which are heritable and may have consequences for reproduction. 
Following the statement, information on significant health related risks that can be 
treated effectively or preventively (category 1) should be passed to the patient. 
Context-related decisions have to be made in case of other findings. The statement 
summarizes that communicating risks of diseases lacking treatments (category 2) as 
well as characteristics bearing a slightly modified risk to develop a particular disease 
(category 3) is of limited value. A 2016 statement by the German Research Foundation 
(DFG) on “human genome sequencing - challenges for a responsible application in 
the sciences” recognised the value of this categorization of additional findings and the 
attendant recommendations. 
 
The Heidelberg-based interdisciplinary EURAT Group (Ethical and Legal Aspects of 
Whole Genome Sequencing) published a “Position Paper: cornerstones for an 
ethically and legally informed practice of whole genome sequencing”, initially in 2013 
with a revised version in 2016.50 The position paper contains a code of conduct for 
researchers (as distinct from treating physicians) involved in genomic research, as 
well as two participant consent templates. The position paper distinguishes two sorts 
of research findings: findings of individual health relevance for the patient that pertain 
directly to the sequencing request and are within the scope of actual investigation 
(“primary findings”), and “additional findings”, that is findings of health relevance which 
are non-intended and are beyond the scope of the original investigation. Echoing 
previous debates, the authors find the term “additional finding” more appropriate than 
“incidental finding” since even though it refers to unsought findings, researchers can 
generally expect to encounter findings of individual health relevance for patients when 
engaging in NGS analyses, so that the findings do not truly occur ‘incidentally’ even 
though they are non-intended. 
 
The EURAT position paper makes the following recommendations: 
1. As NGS techniques used in research may not be approved for clinical care, all 
findings from research (primary findings and additional findings) need to 





2. Primary findings should always be returned if they can be combined with 
existing knowledge and methods to provide treatment and care measures 
tailored to the patient’s specific condition and needs, and if the patient has 
consented. 
3. Reporting of additional findings should be part of the informed consent process. 
The patient has the right and burden of deciding whether or not additional 
findings are to be reported and if so, which findings they want to know.  
4. The physician in charge must decide whether routine laboratory diagnostics will 
be performed in order to validate the findings and, depending on the results, 
communicate them to the patient. 
5. The researcher has a duty of care to notify the responsible physician of all 
primary and additional findings that have been recognized as medically relevant 
for the patient, if and only if the researcher has the awareness that, in the 
absence of this knowledge, the patient would be subject to additional harm or 
increased suffering, and if the patient’s statement of consent does not rule out 
such reporting. 
6. The researcher is not obligated to engage in the active or deliberate search for 
findings beyond the specified context of a sequencing request.    
The last element (6) implicitly refers to (the concept of) secondary findings as defined 
in this handbook (results identified based upon intentional interrogation and beyond 
the original scope/the patient’s treated clinical condition). The EURAT statement 
rejects the idea of a moral or legal duty of researchers to actively search for findings 
of individual health relevance beyond the scope of investigation or disease. The 
EURAT Group also explicitly rejected two elements proposed by the 2013 ACMG 
recommendation:  i) that pre-symptomatic and untreatable findings in paediatric 
patients be returned, and ii) that pre-specified findings be reported back to adult 
patients with no option to opt-out.  
 
2.5 France 
 In France, genomic sequencing technologies have been used in the context of 
cancer and rare diseases for a number of years, but primarily in the context of clinical 
trials, research or clinical research projects. Only a handful of teams are using whole-
exome and whole-genome sequencing tests as opposed to gene panels, which are 
more widespread. Indeed, neither WES or WGS are listed in the National Biology 
Table, which lists approved and priced acts to be reimbursed by the publicly funded, 
universal social security system. Until recently, there were no official French guidelines 
framing the return of secondary findings. Teams that had been pioneering the clinical 
use of these tests, therefore adapted European51,52 or American guidelines8 in order 
to establish return of results protocols that they thought would respect the best interest 
of patients53. Striking the right balance between these guidelines is challenging, 
knowing that the ESHG recommends that measures should be taken to limit risks of 
secondary or incidental findings as much as possible. Without hunting for a specific 
list of variants, they would then decide to return only actionable individual findings on 
a case-by-case basis, after collecting specific consent from patients and families, and 
through a consensual, collegial decision involving biologists, clinical geneticists, 
medical doctors familiar with the case and bioinformaticians. 
 
 However, the situation has recently changed considerably. In 2016, the Agency 
for Life and Health Sciences (Agence Nationale pour les sciences de la vie et la santé, 




medicine in France, entitled “genomic medicine France 2025”54. The final 
recommendations stemming from the plan mandate the establishment of 12 
sequencing platforms throughout the territory of France, the first two having already 
been identified by early 2018. The plan sets a target of sequencing over 200,000 
genomes by 2025, including cancer and rare disease patients. As part of the plan, a 
specific WES/WGS consent form will be established, and a decision will be made on 
the best way to handle secondary findings at the national level.  
 
 In addition, the French Society for Personalized and Precision Medicine 
published recommendations on the return of actionable secondary findings in cancer 
genes55. This guideline, which specifically excludes paediatric-onset conditions, lists 
36 genes in which variants are recommended to be returned to patients, including 
quite a few more than the ACMG recommendations. It also recommends a two-step 
consent, where patients are consented for the return of secondary findings not only at 
the pre-test counselling session, but also once the primary results are returned to 
them, in order to ensure they have a chance to revise their preferences at this point. 
It will be interesting to observe the uptake of these guidelines in practice. 
 
2.6 Canada (Quebec) 
 In Canada, there are two guidelines that include recommendations on the return 
of secondary findings to patients or research participants. In 2015, the Canadian 
College of Medical Geneticists (CCMG) published a Position Statement intended to 
“provide recommendations for Canadian medical geneticists, clinical laboratory 
geneticists, genetic counsellors and other physicians regarding the use of genome-
wide sequencing of germline DNA in the context of clinical genetic diagnosis”56. While 
each province and territory in Canada is responsible for determining clinical test 
reimbursement, this position statement aimed to provide non-binding guidance to 
increase consistency in clinical genomic testing offered to patients across Canada. 
Although the CCMG is aligned with the ESHG in stating that incidental findings should 
be avoided as much as possible56, they also value individual laboratories’ autonomy 
and suggest ways to frame their offer to report such findings. 
 
 The fundamental document regulating research ethics is the Tri-council policy 
statement on the Ethical Conduct for Research Involving Humans, which stems from 
the Canadian Institutes of Health Research, the Natural Sciences and Engineering 
Research Council of Canada and the Social Sciences and Humanities Research 
Council of Canada. (TCPS2). This document is not legally binding in Quebec, but it is 
the gold standard followed by all ethics committees that oversee research in all 
provinces and territories in Canada. This guideline provides details on the 
requirements for researchers to establish a clear plan “for managing information 
revealed through genetic research”. Researchers are free to decide whether to share 
individual findings with participants, or to exclusively disclose “non-identifiable 
research results”. In case researchers do decide to return individual results to 
participants, measures should be taken so that they can: 
“(a) make informed choices about whether they wish to receive information about 
themselves; and 
(b) express preferences about whether information will be shared with biological 





 The “right not to know” is specifically mentioned, and researchers are required 
to detail how the return of results will be organized, whether directly or through a 
healthcare provider, as long as appropriate genetic counselling options are given to 
patients when necessary. 
 
 In 2014, the Quebec Ministry of Health and Social Services (MoHSS) 
specifically excluded the use of WES and large gene panels in patients, by adding 
them to the to the “list of analyses not covered by Quebec medical insurance and not 
reimbursed in the framework of the Authorisation and reimbursement mechanism for 
medical biology analyses not available in Quebec”57. Teams who wanted to offer 
those tests to patients were effectively funding them through research projects, and 
observed the TCPS2 guidelines regarding the return of secondary findings. However, 
in August 2018, the Minister of Health and Social Services Gaetan Barrette 
announced the creation of the Quebec Center for Clinical Genomics, located at the 
Ste Justine hospital in Montreal. The decision for the sequencing platform to be 
located in Ste Justine is mainly based on the fact that in October 2014, they initiated 
an Integrated Clinical Genomic Centre in Pediatrics58 at the same site. That platform, 
based on the Illumina 2500 technology, started functioning in the summer of 2015, 
offering sequencing services to researchers in Ste Justine and other institutions in the 
province, and is in the process of obtaining CLIA and ISO certification to be able to 
offer clinically validated tests. Teams throughout the province will shortly be able to 
request WES or WGS tests, and a standard consent form, including guidance on how 
to handle secondary findings will be established, most probably using the CCMG 
guidelines as a starting point. 
 
2.7 Singapore 
 During the rise of genomics, individual research centres and clinical units in 
Singapore pursued their own genomic programmes. As a result, practices concerning 
secondary findings varied depending on institutional capacity, expertise and ethical 
judgment. More recently, Singapore’s Ministry of Health has begun exploring the 
potential of large-scale genomics programmes for healthcare, and the National 
Precision Medicine Alliance has been formed as a ground-up coalition to harmonise 
existing genomics activities. The development of national regulations and guidelines 
concerning secondary findings are also providing further standardisation, depending 
on whether they occur in the research or clinical context. 
 
 Translational genomics research in Singapore is regulated by the 2015 Human 
Biomedical Research Act.59 Amongst other provisions, the Act requires the informed 
consent process to disclose whether incidental findings will be returned. ‘Incidental 
findings’ are broadly defined in the law to include what are known internationally as 
‘secondary findings’. In this section, the terms are used interchangeably. Regulations 
further specify that it is the responsibility of research institutions to establish 
institutional policies concerning the return of such findings.  As of this writing, local 
institutions and their IRBs are in the process of developing reporting policies. 
 
 Some further guidance can be found in the Singapore Bioethics Advisory 
Committee’s 2015 report, “Ethics Guidance for Human Biomedical Research”, which 
states that there is “some duty” for researchers to report clinically significant incidental 
findings.60   Non-clinically significant findings are not discussed, nor does the report 




however, that a reporting plan should be decided prior to commencing a study, and 
that the plan should be disclosed to participants – with the option of not receiving any 
findings, should researchers choose to make these available. 
 
 Clinical genomics is regulated separately.  Beyond general professional ethics 
standards governing clinical practice, in June 2018 Singapore’s Ministry of Health 
issued a Code of Practice on the standards for clinical and laboratory genetic and 
genomic testing services.61   The Code defines three tiers of practice corresponding 
to the risk and complexity of the genetic test, with germline testing (excluding 
pharmacogenomic associations), occupying the highest tier.  At that level, genetic 
counselling must be provided both before a genetic test is conducted, and at results 
disclosure.   
 
 The pre-test counselling must include discussion of potential incidental findings, 
detail the particular laboratory’s policies on the matter, and explore the ramifications 
(clinical, social, psychological, etc.) on the return of results.  In addition, the consent 
process must allow patients to opt in or opt out of receiving such findings.  Notably, 
the guidelines do allow space for a laboratory to decline to report any incidental 
findings, as long as that policy is made clear to patients during pre-test counselling 
and adhered to later on.  No definition of ‘incidental findings’ is given, nor is a standard 
for generating or reporting such findings (reproductive relevance, clinical relevance, 
clinical actionability etc.) provided. Instead, laboratories are advised to consider the 
clinical actionability and patient consent preferences and document the management 
of incidental findings in their standard operating procedures. Given that there are 
limited accredited genetic counsellors and clinical geneticists practising in Singapore, 
the clinical guidelines stipulate the pre and post genetic counselling can also be 
performed by a medical practitioner with several years’ experience in clinical genetic 
counselling.   
 
 One particular risk that any pre-test counselling session should discuss is 
genetic discrimination.  Unlike other countries, such as the US, Canada or the UK, 
Singapore currently lacks a legal prohibition or moratorium on genetic discrimination 
in insurance or employment.  While there is a universal health insurance programme 
through MediShield Life, many Singaporeans ‘top up’ with private health insurance 
along with life or disability insurance policies.  Secondary findings, then, pose 
theoretical but non-trivial risks to Singaporeans: when signing up for an insurance 
programme after having a genetic test, there is no legal prohibition on asking whether 
the purchaser knows they are a carrier of certain traits affecting disease risk.  Likewise, 
similar issues could be experienced when seeking employment. Unless a moratorium 
on genetic discrimination is issued in future, the risk of discrimination needs to be 
disclosed and discussed in the genetic counselling process. 
 
 Despite the diverging regulatory regimes, there are substantial similarities in 
the regulations for returning incidental findings in research and clinical settings.  In 
both cases, a plan must be in place prior to the test, disclosed to the volunteer/patient, 
and the option given to opt in or opt out.   The type of findings  returned, or whether 
there is a duty to generate secondary findings in the first place is at the discretion of 
the researcher or clinical laboratory.  A substantial point of difference, though, are the 
pre- and post-test genetic counselling requirements present in clinical testing, but not 




for large-scale genomics research, though in situations where clinically relevant 
findings could be generated, compromise solutions like standardised decision aids 
(videos, interactive apps, brochures, etc.) are worth exploring. 
 
 Clinical care and research activities are not always clearly delineated, however.  
For example, the SingHealth Duke-NUS Institute of Precision Medicine (PRISM) was 
established to transition research participants with significant genomics findings into 
the healthcare system for ongoing care. PRISM analyses genomic data from 
volunteers recruited for genomics research.  Participants are then given relevant 
information from genetics specialists, and after counselling and consent, receive 
clinically validated secondary findings that are transferred to the clinical setting for 
follow-up care.  Integrating genetic research units into clinical practice in this way 
requires substantial scientific, organizational and infrastructural investment, but may 





 In Estonia, research in the field of genomics and its transfer into the healthcare 
system has been closely intertwined with the developments of the Estonian biobank 
which is held by the Estonian Genome Centre, University of Tartu.  The population 
biobank was founded in early 2000 with the long-term goal of benefiting the health of 
the public. Between 2002 and 2011 close to 52 000 participants were recruited, and 
by now all of the subjects in the biobank have been genotyped. In addition, the 
genomes of 2,600 and exomes of 2,500 participants have been sequenced. Although 
the primary goal of the biobank was research62, the tremendous amount of genetic 
data that produced raises the question of incidental findings.  As there are no national 
guidelines concerning secondary or incidental findings in population biobank settings, 
the practice of the Estonian biobank is based on the Estonian Human Genes Research 
Act which regulates its work. This legislation states that the biobank participants have 
the right to know results and the right to genetic counselling.63 Currently, results are 
only offered on a project based manner through the biobank.64 For example, 
participants detected to carry a pathogenic finding associated with hereditary breast 
and ovarian cancer or familial hypercholesterolemia have been re-contacted and 
invited to participate in a project where results are returned upon consent.65 A second 
blood sample is taken to confirm the results, and validated findings are returned to the 
participants during a face-to-face genetic counselling session. Carriers are referred to 
clinical specialist for follow-up and encouraged to contact their first and second degree 
relatives to introduce the option of cascade screening. The response, emotions and 
general opinion of the participants are surveyed prior to and after the counselling 
session to inform future projects. As of September 2018, over a thousand individuals 
have received individual results and counselling at the biobank. 
 
 Clinical exome sequencing was first implemented in 2011 through a research 
collaboration between the Estonian Genome Centre and the children’s hospitals of 
Tallinn and Tartu. The service was recognized as a diagnostic analysis by the Estonian 
Health Insurance Fund in 2014. The indication for exome sequencing covered by the 
health insurance fund is “an undiagnosed disease of suspected genetic aetiology, 
where more specific genetic analysis is not available, difficult to specify due to genetic 




sequencing mentions a small possibility of clinically significant findings unrelated to 
the indication for testing. When consenting for exome sequencing, one can decide to 
opt in or opt out of being informed of incidental findings. The consent form refers to 
the ACMG recommendations for reporting incidental findings as well as mentioning 
the option of other genetic findings that could be of significant importance to the patient 
or relatives.66 Based on these guidelines, the expert board of the Department of 
Clinical Genetics of Tartu University Hospital decide which findings are reported.   
  
 In 2015, a national personalized medicine pilot project was initiated based on 
the Estonian biobank.67 The initiative foresees incorporating the genotype data of 
biobank participants into the national health information system to allow better targeted 
methods for health care and disease prevention. The approach involves targeting rare 
disease causing mutations (e.g. BRCA1/2, LDLR, APOB, PCSK9), polygenic risk 
scores for common diseases (coronary artery disease, type 2 diabetes), and 
pharmacogenetics. As part of the pilot phase of the initiative, clinical flagship projects 
have been launched involving personalized risk prediction and treatment of breast 
cancer and cardiovascular disease in clinical settings. In 2018, the government 
allocated funding for the recruitment of an additional 100 000 biobank participants.68 
Within the first five months over 52 000 individuals signed up and consented to 
participate in the biobank project.  
 
2.9 Japan 
In the late 1990s formal discussions about ethical issues regarding human 
genome research at the government level started in Japan. At that time, the Human 
Genome Project, of which Japan was a member, was making a rapid progress. At the 
same time, large genomics research programs were being promoted by the 
government in Japan. With this background, the Japanese government set up the 
Bioethics Committee in the Council for Science and Technology to lay out national 
frameworks to deal with ethical and social issue of genomics research.69 In 2000, the 
committee issued a report on “The Fundamental Principles of Research on the Human 
Genome.” In this document both the right to be informed and right not to be informed 
were stated. Based on this document, new government guidelines for genomics 
research, “Ethical Guidelines for Human Genome/Gene Analysis Research (Ethical 
Guidelines)” were established in 2001.70 Although the Ethical Guidelines are not 
legally binding, they have been serving as guiding regulations across the country for 
more than 15 years. The Ethical Guidelines have a section describing the right of 
research participants to be informed of the research results, but also have stipulations 
on the exemptions from being informed of results.  The latter includes when the 
disclosing the results is judged likely to harm the life, body, properties and other rights 
and interests of research participants. Until around 2015, many of the basic genomics 
research projects utilizing human samples did not adopt a policy of disclosing even 
primary results from genomic analysis. The main reason was because the results of 
the genomic analyses did not produce clinically significant data.  
 
This situation began to change rapidly around 2015. There were several 
important events behind the change.  First, new laws were enacted to promote and 
revitalize the Japanese policy for medical research in the face of an aging society. 
These were the Act on the Promotion of Healthcare Policy and the Act on the 
Independent Administrative Agency of Japan Agency for Medical Research and 




established in the Cabinet in 2014.71 One of the committees created within the HHP, 
the Council for Realization of Genomic Medicine (CRGM) began to steer the national 
policy for genomic medicine. A key report on the genomic medicine published by the 
CRGM in July 2015 contained a section on hurdles for implementation of genomic 
medicine in clinical settings. Within the section, it was stated that incidental findings 
were a challenging issue and requested specific government funded projects to work 
on it. The second important event was the establishment of a new funding agency, 
AMED in 2015 that coordinates funding activities for medical and translational 
research across the Ministries. It began to promote genomics research projects that 
were more relevant for clinical medicine. Even projects aiming at basic understanding 
of mechanisms of diseases, researchers were required to explain potential clinical 
outcomes of the research.  
 
The first large project that worked on the issue of incidental/secondary findings 
was funded by the AMED and led by Dr. Hitoshi Nakagama, the director of the 
Research Institute of the National Cancer Centre. It aimed to carry out large-scale 
clinical sequencing in several disease areas including cancer, neuro-muscular 
diseases, cardiovascular diseases and others, although in the strict sense the 
sequencing was still research stage. The project contained a research group for ethical 
issues with the author of this section, Professor Kato of Osaka University, as one of 
its members. The group conducted literature surveys and held meetings with 
genomics researchers who were trying to implement clinical sequencing. It became 
clear that in some of the cancer areas, additional findings were being returned to 
sample donors, while researchers were not returning those findings in non-cancer 
areas. The final report published in March 2017 included five key areas of 
recommendations. They include the importance of providing genetic counselling, long-
term follow up of patients and families, capacity building of relevant specialists such 
as data scientists, genetic counsellors, ethicists et cetera. Establishment of measures 
to prevent genetic discrimination was also mentioned.72 Another research project is a 
large national genome cohort, the Tohoku Medical Megabank, which was set up after 
the Tohoku earthquake.73 It was set up by the government as one of the projects for 
restoration of the area and has collected samples and data from about 150,000 healthy 
people.  The Megabank also completed whole genome analysis of several thousand 
samples. Utilizing the results, they have started to return the genomic analysis results 
of familial hypercholesterolemia.  
 
The two latest projects that are working on the issue of additional findings are 
also funded by the AMED. One of the projects, led by Professor Shinji Kosugi, is 
working on the establishment of a practical policy for returning genomic results in the 
clinical setting.  In this project, the term “secondary finding” is used for germ line 
variants of inherited diseases (mostly cancer) that could be found during the analysis 
of cancer tissues and blood samples using gene panels. The first draft was published 
in March 2018 and describes necessary issues for consideration at the stages of pre-
testing explanations to participants, informed consent, disclosure of results, etc. For 
example, the draft report recommend that at the time of informed consent, patients are 
given an explanation of the possibility of secondary findings and the opportunity to 
state their preferences of receiving the results. Another new project, known as the 
Leader Project (Leading the way for genomic medicine) is looking into the 
requirements when researchers have to deal with the secondary findings in the 




by March 2019. One further recent activity is worth mentioning. Japan began to 
perform “cancer genomic medicine,” as a part of the government initiatives to 
implement genomic medicine begun in 2017.  Using gene panels to analyse cancer 
tissues, 11 designated hospitals as well as approximately 100 associated hospitals 
will perform cancer treatment. It is of note that none of the above activities has 
published a list of genes that are the targets of secondary findings. 
  
In conclusion, a dramatic change has happened in term of the policy 
concerning secondary findings in genomic medicine in Japan over the last several 
years. A remaining challenge is to further elaborate the policy, particularly for the 
clinical settings. Deciding which genes (variants) need to be considered as targets of 
returning as secondary findings is an issue that still requires further work. It will also 
be necessary to work with patients to incorporate their perspectives. Effective 
communication and collaborations among key stakeholders including medical 
professionals, policy makers and patients will be the key to maximizing the benefit for 
the society.    
 
2.10 Summary 
 The above accounts demonstrate there is no single, straightforward method for 
implementing genome sequencing as a routine clinical procedure. As seen in almost 
all the national case studies, the initial development of medical genomics has taken 
place in research settings and subsequently moved into clinical practice. There are 
important differences between the research and clinic settings. Medical research is 
understood as experimentation designed to produce generalizable knowledge. 
Medical ethicists over the years have emphasised the importance of ensuring that 
patients taking part in medical research do so on the clear understanding that they 
should not expect any therapeutic or diagnostic benefit from participation (so called 
therapeutic or diagnostic misconceptions). Return of findings to participants is rarely 
expected or even considered suitable as their clinical significance is often unknown. 
The regulation of medical research, through national and international laws and 
mechanisms such as Institutional Review Boards or Hospital Research Ethics 
Committees tends to focus on protection of human participants from undue harm by 
managing the risks to which they are exposed. Research projects also tend to have a 
fixed time limit and budget. In clinical care, by contrast, the injunction to ‘first do no 
harm’ is only a minimum basic requirement and the oversight of care is orientated 
towards securing the best possible outcome for the individual patient, which usually 
means securing evidence-based diagnosis and treatment. This is established in legal 
requirements such as the physician’s duty of care to the patient, the rules for 
establishing medical negligence and the concept of an established ‘standard of care’ 
that physicians and healthcare institutions are obligated to provide. Healthcare 
systems also operate in a different financial setting where costs must be met on an 
ongoing basis, either from a constrained budget in public healthcare settings or 
through the reimbursement policies of different payers (mainly insurance companies 
and employers) in a private system. In either case, there are well-established 
processes of health technology assessment (HTA) designed to assess which new 
processes and interventions represent value for money.   
 
 The very idea of ‘translational’ research was coined to recognise that the 
transition from research to clinical practice is complicated and requires work, 




machine or procedure. It requires finding ways to make that technology work in the 
wider context of a particular healthcare system so that it can move from a successful 
prototype to a widely used, routine process.75 Genomics presents an ‘excess’ of data, 
beyond what is needed for most diagnostic applications. Although unsought findings 
are not unique to WGS, the phenomenon meant that there was uncertainty about how 
to manage this ‘disruptive’ feature; for example, in the UK it remains unclear whether 
the established legal duty of care extends to returning additional or incidental findings 
in genomics to patients (and indeed potentially to their families) and if so, what should 
be returned. In the early stages of translation, individual clinics and hospitals must 
often make decisions about what should be done under conditions of uncertainty and 
a lack of centralised guidance. This means there is a risk of divergent standards of 
care emerging within jurisdictions, something widely seen as undesirable. When a new 
technology like WGS enters the clinical realm there is rarely economic evidence for 
benefit or a clear existing standard of care, and seldom time for new legislation to be 
passed to stipulate exactly how the technology should be used. Instead, there are 
more likely to be ‘inherited regulations’76 devised for earlier technologies, in this case 
genetic testing, and existing institutions and professional bodies that act as an 
authoritative reference point. In this context, the ACMG recommendations that (only) 
a specific subset of genomic variants should be examined for all clinical sequencing 
of patients can be understood as an attempt to generate a standard of care that would 
deal with the problem of unsolicited findings and allow the clinical implementation of 
genomics to proceed.  
 
 At the same time, it is clear from the studies of different territories presented 
above that the ACMG list of secondary findings has not been universally accepted 
(see table 2.0 for a summary). This should not be surprising. The ACMG approach of 
a defined, if flexible, list of specific genomic variants to be designated ‘secondary 
findings’ was developed in the specific setting of US healthcare. Different territories 
have different legal and regulatory systems, different institutions and economic 
underpinnings of their healthcare systems, and different cultural preferences and 
attitudes to topics such as risk and even defining clinical benefit. It is therefore hardly 
surprising that different countries and different regions within federated territories, took 
divergent stances on secondary findings as a solution to the problem of unsolicited 
genomic results. Although the ACMG list of secondary findings do not act as a 
universal standard of care, even in the US, they did succeed in driving forward the 
international debate, by prompting responses about how best to proceed, in each 
jurisdiction. Even though the outcomes are distinctive, there is a remarkable similarity 
in the mode of responses in different jurisdictions. Only Germany has a statutory 
provision that relates to secondary or incidental findings, and the 2009 German Gene 
Diagnostic Act does not actually use those terms at all, but introduces its own lexicon 
of ‘unexpected results’ arising from ‘surplus information’. However, most territories 
deployed some form of non-binding but centralised guidelines on what best practice 
might look like for clinicians. These were mainly issued by existing professional bodies 
such as the ACMG, the ESHG, Canadian College of Medical Genetics, German 
Society of Human Genetics or the French Society for Personalized and Precision 
Medicine. Again it is not surprising that the majority of these bodies were originally 
concerned with the clinical provision of genetic services, as the obvious antecedent to 
clinical genomics. Other entities providing guidance were national bodies concerned 
with health research- as the originating point of medical genomics- such as the 




Realization of Genomic Medicine (CRGM) in Japan, the German Ethics Council and 
the Berlin-Brandenburgische Akademie der Wissenschaften, Singapore’s Ministry of 
Health or the Estonian Genome Centre.   
 
 The latter example is also a reminder of the importance of projects, especially 
state-supported national projects, to build translational infrastructure such as biobanks 
to support clinical genomics.71 Most of the examples considered above have some 
sort of large-scale nationally supported translational genomics venture. Some such as 
the 100,000 genomes project, Genomics Australia, the Aviesan plan for a network of 
12 genome sequencing centres in France, the or the Quebec Centre for Clinical 
Genomics are new endeavours. Others build on existing infrastructure like the 
Estonian biobank, the Tohoku Medical Megabank, or the recent announcement that 
the UK government plans to extent the 100k Genomes project by sequencing a further 
500,000 genomes from existing samples contained in the UK national biobank. In both 
cases, these translational projects provide a space where clinical implementation of 
genomics, including returning results, can be tested and evidence of what works or 
does not work generated and evaluated. They are also sites where future national 
policies on secondary or additional findings are likely to be formulated. 
 
Table 2.0: Overview of stances on secondary and additional findings in national 



















USA No ACMG guidelines 
 
Recommend return of 
ACMG list of secondary 
findings 









Advise against return of 





specific list of 
additional findings on 
an opt-in basis 
Australia No NHMRC ‘Principles’ 
HGSA commentary 
on ACMG Guidelines 




Advise caution and 








Alliance for the 
state of Victoria 
 
Pilot return of project 
specific list of 
additional findings on 
an opt-in basis. 
Australian Genomics 
policy is in 
development 
Germany German Gene 
Diagnostic Act 
(Gendiagnostikgesetz, 
2009) states that 
potential for 
‘unexpected findings’ 
must be discussed 
with patients. 
German Ethics 
Council statement on 
“the future of genetic 
diagnostics” 
Patients must have 
right to refuse 
additional findings. 
Only additional findings 
indicating significant 
risk of treatable or 
preventable disease 








Not clear, but see 
section 2.4 for 
guidelines from 
German Society of 
Human Genetics 
(GfH), German Ethics 
Council and EURAT 
group.  
France No French Society for 
Personalised and 
Recommend return of 
expanded list of 
secondary findings 
Aviesan network 


















findings as much as 
possible but respect 
autonomy of individual 
labs and clinics to set 
own policy 
Regional: Quebec 




Singapore Human Biomedical 
Research Act (2015) - 
only applies to 
research not to clinical 
practice 
Ministry of Health 
Code of Practice 
Laboratories have 
some scope to set own 
policy on returning 
incidental findings 
provided pre-test 





National Policy in 
development. 
PRISM returns 
project specific list of 
additional findings 
Estonia No Estonian Genome 
Centre policy 
Expert board of the 
Department of 
Clinical Genetics of 
Tartu University 
Hospital 
Return of findings 
relating to selected 
cancers and familial 
hypercholesterolemia 
to biobank participants, 
Return of incidental 
findings as assessed by 
the expert board, for 
clinical genomics 
collaboration between 
the Estonian Genome 
Centre and children 




medicine pilot of 
the Estonian 
national biobank 
Pilot targets specific 
pre-defined variants 
associated with 
disease risk  




have right to findings 
but also a right to opt 
Tohoku Medical 
Megabank 








projects to develop 
policy on incidental 
and secondary 
findings 
out. In practice most 
findings were not 
returned 
New reports in 2017 
and 2018 permit return 










3) Emerging and future scenarios 
 This section looks at a number of areas where additional or secondary findings 
raise new issues, or require a different perspective, in comparison to clinical genomics 
for adult patients with known diseases. The areas covered are; paediatric and prenatal 
applications of genomics; nutritional and ‘wellness’ genomic services; and the storage 
and return of sequence data to patients and research participants. Although disparate, 
each area represents an extension to, or, in the case of wellness genomics a spillover 
from, adult clinical practice. It has been noted that children challenge classifications 
and standards build around adults because they must be considered both a group in 
their own right and in terms of the future adults they will become.77  In medicine, 
children are recognised to require special rules and procedures in domains from giving 
consent to participating in clinical trials, and returning secondary or additional findings 
from genomic sequencing in children also raises novel concerns about variants 
associated with adult versus childhood onset conditions. Wellness genomics goes 
beyond what is usually regarded as ‘clinical’ both in the sense that wellness genomic 
tests provide advice on lifestyle, diet, and other social activities like exercise, but also 
in the way that the online marketing of many wellness genomic services bypasses 
traditional clinical institutions and the regulations by which they are governed. Finally, 
return of sequence data is not a novel application of genomics, but rather an additional 
concern raised by the storage and digital portability of genomic data produced for the 
clinical applications discussed elsewhere in this chapter. Again, it is a domain where 
issues of secondary findings inform the broader discussion of what best practice looks 
like. 
 
3.1 Pediatric, neonatal and prenatal genomics 
 The majority of policies on return of secondary or additional findings described 
above relate primarily to the clinical use of NGS techniques in adults. However, WGS 
WES and targeted gene panel testing are increasingly being used, or considered for 
use, in paediatric populations.78 The application of genome sequencing in paediatric 
populations involves additional concerns beyond those discussed for adult populations 
in term of how to manage secondary and additional findings.  At present the most 
frequent paediatric use of WES and WGS is in children with rare diseases.79 These 
tend to be children with highly variable symptoms, such as intellectual disability, 
developmental delay or congenital malformation, and where there is frequently genetic 
heterogeneity between cases. Here, sequencing is used primarily as an aid to 
diagnosis. The meaning of sequence variants is interpreted in light of the patient’s 
symptoms, as described in more detail in section 2.2. 
 
 An example of a possible secondary finding in this scenario, proposed by 
Klugman and Dolan,80 would be finding a mutation in the BRCA1 gene conveying 
increased lifetime risk of breast and ovarian cancer, in a two-year-old child being 
evaluated for developmental delay using WGS.  Returning this result requires consent 
of the child’s legal guardians. Where these are the genetic parents of the affected child 
the result also has implications for them and for any related siblings of the affected 
child. One or both parents may be a carrier of the detected mutation as might an 
asymptomatic sibling. As with adult patients, the implications of genomic sequencing 
and the potential for findings to affect both patient and direct relatives need to be 





 WGS could also potentially be used to carry out population-wide screening of 
children for a range of conditions. The most common vision is that this would be 
integrated into existing public health programmes aimed at newborn children. Although 
not currently practiced, the idea of neonatal WGS has been suggested by several 
prominent sources; it was discussed as far back as a 2003 report on the use of genetic 
services in the UK’s National Health Service81 and has been raised by the Director of 
the US National Institutes of Health, Francis Collins, on more than one occasion.82 
 
 Screening is not diagnosis. As discussed briefly in relation to the Geisinger 
Health System My Code Community Health Initiative, (section 2.1), screening involves 
systematically testing asymptomatic individuals with the aim of detecting conditions or 
increased risk of disease in individuals, who can then be followed up with further 
confirmatory diagnosis and treatment. Current neonatal screening polices vary widely 
between countries in terms of which conditions are tested for and how many conditions 
are included in the screening procedures.79 Moreover ACMG has explicitly stated that 
its list of recommended, clinically actionable variants does not apply to neonatal 
screening.81 Any use of genome sequencing for neonatal screening will therefore need 
a policy on what to look for and which findings to return to parents. Commentaries on 
potential neonatal use of WGS have stressed that the clinical justification for screening 
is to identify conditions where preventative action or treatments can be applied during 
early childhood.79,82 Screening for, or returning secondary or additional findings 
relating to, adult onset diseases is contrary to that rationale, although there is a further 
complication where a mutation indicating an adult onset condition could also have 
implications if one or both parents are carriers.  
 
 Another recent development has been widespread global uptake of genome-
based non-invasive prenatal testing (gNIPT) for the detection of foetal aneuploidy, 
based on cell free foetal DNA fragments found and analysable in the circulating blood 
of a pregnant woman.83 These fragments are reliably available for analysis from 10 
weeks of pregnancy so testing can be done relatively early (although where it is 
necessary to send samples by post to another country this can take up to 2 weeks).84 
Cell free DNA fragments are assumed to originate from cells of the placenta, so they 
do pose a problem with confined placental mosaicism.  Nonetheless, a recent 
systematic review of gNIPT for foetal chromosomal aneuploidy85 found that genome-
based testing methods appear to be sensitive and highly specific for detection of foetal 
trisomies 21, 28 and 13 in high risk populations and that there is a paucity of data on 
the accuracy of gNIPT as a first-tier aneuploidy screening test in a population of 
unselected pregnant women. The authors concluded that on the basis of their review, 
which examined 65 studies of 86,139 pregnant women, gNIPT was not sufficient to 
replace current invasive diagnostic tests and that invasive foetal karyotyping is still the 
required diagnostic approach to confirm the presence of chromosomal abnormality 
prior to decision making. However, Lewis et al86 have found NIPT for the common 
aneuploidy Trisomy 21 to be acceptable to a vast majority of women surveyed in 
England. They concluded that uptake of the test is likely to be high, and includes 
women who currently decline screening as well as those who will use the test for 
information only.  
 
 The discovery of the availability of the whole foetal genome in cell free form in 
the circulating blood of a pregnant woman84 also raises questions not only about the 




and who is responsible for ‘re-contacting’ the future child and/or parents with genomic 
information, particularly should it be relevant to the health and/or healthcare of the 
future child. While some work has been done recently on recontacting in Europe87 this 
is clearly an area where consensus about appropriate action is lacking, and where 
resources and desires for ‘best practice’ may not coincide. For both neonatal and 
prenatal WGS or WES, commentators have also raised the concern that returning data 
about genomics variants whose significance is uncertain, or where they relate to adult 
onset disorders could result in stress and unwarranted concern at an already stressful 
time for many parents and could have potentially deleterious qualities for the 
developing parent-child bond.79,81 
 
 The meaning of genomic variants depends on correlating sequence variants 
with phenotypic data from patient populations. This is especially challenging for 
neonatal and prenatal populations where limited datasets exist and most of the 
population are asymptomatic. Unlike the diagnostic use of WGS in children with rare 
diseases, there is no option for physicians to iteratively interpret the neonatal or 
prenatal sequence data in the context of the patient’s phenotypic profile.81 The 
meaning and interpretation of variants is likely to change over time as more data from 
more cases is added to databases77, and this is especially the case for non-Caucasian 
groups who are often poorly represented in existing registries and datasets. For all 
these reasons, working out what, if any, data is cost effective, clinically useful, and 
ethically appropriate to return is especially difficult for any attempt to deploy genomics 
for neonatal or prenatal screening. A further issue is that establishing these genome-
phenotype correlations requires making both sequence data and associated clinical 
information available to researchers and other clinical groups. Where existing data is 
limited, sharing combined datasets is likely to put the patient at greatest risk of 
subsequent identification, where they are least likely to receive any direct benefit from 
the act of sharing.88 
 
3.2 Wellness genomics 
 Wellness is a state that encompasses physical, mental and social wellbeing, 
and for some, is a lifelong pursuit. Personal genomic testing, and in particular, that 
based upon nutritional genomics, offers new potential to those hoping to attain an 
optimal state of wellness. Nutritional genomics refers to the evolving study of gene-
nutrient relationships, including how genetic variations influence the body’s response 
to nutrients (nutrigenetics) and how nutrients mediate genomic function 
(nutrigenomics).89 Nutritional genomics has gained increased research attention given 
its potential to inform an individual’s optimal diet. Tailoring diet to an individual’s 
genotype is not a new concept; diets low in phenylalanine have been prescribed to 
people with phenylketonuria, a genetic disorder of amino acid metabolism, since the 
mid-20th century. The application of nutritional genomics, however, goes beyond the 
clinical management of monogenic conditions, instead aiming to mitigate polygenic 
disease-risk in otherwise healthy populations. Initially, nutritional genomics was 
framed to potentially revolutionize the field of human nutrition.  
 
 Recently, the marketing rhetoric of ‘wellness genomics’ has emerged. In many 
instances, wellness genomic tests expand beyond nutritional genomics, not only 
offering consumers dietary advice, but insight into fitness regimens, skin care, 
response to medications (known as pharmacogenomics) and even personality traits. 




wellness genomic companies have moved to a direct-to-provider model.90 In this 
model, a healthcare provider facilitates testing for their clients. In these instances, the 
healthcare provider must undergo accreditation with the chosen testing company 
before offering testing; however, what the training involves, and how competency is 
assessed, is unclear. A recent content analysis of online wellness genomic information 
has highlighted that in Australia, complementary/alternative medicine providers have 
enthusiastically adopted this testing.91 Both the wellness genomics testing companies, 
and the associated complementary/alternative medicine providers, heavily market 
their services online. Nutritional genomics is described as the future of healthcare, 
suggesting that genomic wellness tests are a superior tool for facilitating health and 
wellbeing. Websites also claim that genomic wellness tests will reduce the guesswork 
around diet and lifestyle choices. In particular, websites use language such ‘optimize’ 
and ‘transform’ to describe how the test results would impact on health. Similar to other 
direct-to-consumer personal genomic testing advertising, the notion of consumer 
empowerment was paramount.92 Unfortunately, many of the benefits of nutritional 
genomics have yet to materialize in most instances. 
 
 The ACCE Framework93 provides a guideline for assessing the quality of 
genetic tests, especially those used to screen populations, against four criteria. Each 
letter represents one of the four criteria of the framework. The first, analytical validity, 
refers to the ability of a test to accurately identify the gene or genetic variation it intends 
to. The second, clinical validity, considers the reliability of a test to determine disease-
risk based on a specific genetic variation. The third, clinical utility, refers to the 
usefulness of test results for informing healthcare decisions. The fourth criterion 
encompasses ethical, legal and educational domains.  Testing company websites 
promote the tests as being evidence-based and scientifically up-to-date; some even 
list the clinical team involved in identifying genetic variants based on the literature.91 
However, many gene-nutrient interactions currently lack sufficient clinical validity, yet 
are still included in these tests.94  Markers of poor health, such as obesity and high 
cholesterol, which wellness genomics attempts to combat, are mediated by the 
combination of genetic and non-genetic factors. Wellness genomic tests often do not 
take into consideration the polygenic nature of non-communicable diseases, the 
impact of the environment or cross-cultural differences.95 Further, the nutritional 
genomics industry currently lacks regulation, meaning testing companies are free to 
base dietary advice on whatever evidence they choose, resulting in consumers 
receiving different risk-estimates depending on the company. Recognizing this, 
Grimaldi et al  recently published a set of guidelines for assessing the validity of gene-
nutrient interactions, which may produce more standardized tests in the future.94 
 
 Regarding clinical utility, research indicates that even when given genotype-
based diets, people are unlikely to make lasting changes to their diet and lifestyle.96  
However, interviews with 16 Australian adults have revealed that wellness genomic 
testing is particularly enticing to the chronically unwell.97 Disheartened by perceived 
negative interactions with the conventional healthcare system, the majority of these 
participants turned to complementary/alternative medicine in search of answers. To 
them, wellness genomic testing represented a new and final hope to get to the “root 
cause” of their chronic health concerns. Despite describing the test as “empowering” 
and “validating”, the participants’ self-reported health improvements were small. Most 
had been prescribed new diets and a variety of supplements, but found the process 




remained positive about their continuing pursuit of wellness, the general, healthy 
population looking for an ‘easy-fix’ to their diet may experience disappointment or 
‘buyer-regret’.  
 
 Given that consumers can access genomic wellness tests online or through 
healthcare providers who may or may not have sufficient training to interpret the 
results; issues also arise regarding support given pre- and post-test. Hurlimann et al 4 
recommend all potential consumers be given thorough pre-test counselling to ensure 
informed decisions about testing are made. This is particularly pertinent when 
considering some genetic variants analysed in wellness genomics tests also have 
significant implications for non-diet related health conditions.  Several wellness 
genomic tests use APOE-ε4 to examine cholesterol regulation, without necessarily 
communicating the relationship between APOE-ε4 homozygosity and greatly 
increased risk of Alzheimer’s disease. 98 Recently, Janssens et al published on this 
issue by describing two nutritional genomic research studies in which APOE-ε4 was 
included: one where the association between Alzheimer’s risk  was described briefly 
in the participant information sheet, and the other where no mention of the association 
was made at all.98 The authors highlighted the potential psychosocial implications 
should those research participants homozygote for APOE-ε4 later learn of their 
increased risk of Alzheimer’s disease. However, these concerns had already become 
a reality for one research participant. In 2011, Messner described the case of ‘Josh’, 
an otherwise healthy 40 year old, who participated in a study investigating the impact 
of receiving genetic susceptibility testing on health behaviors.99 After receiving his 
results, he was shocked to learn that Alzheimer’s disease was one of the health 
conditions tested for, and that he had two copies of the APOE-ε4 allele. Josh described 
feelings of hopelessness and despair, and later criticized the ambiguous consent 
process involved in the research. 
  
 APOE-ε4 and Alzheimer’s risk is just one example of secondary or incidental 
findings that could emerge from genomic wellness testing. As research into gene-
nutrient interactions continues, it is likely clinical validity will improve. Whether or not 
nutritional genomics will be the answer for those pursuing an optimal state of wellness, 
however, remains to be demonstrated. 
 
3.3 Storage and return of raw sequence data in the clinical and research settings 
 Currently CLIA regulations (section 493.1105) require storage of analytic 
systems records and test reports –including genomics-based tests - for at least 2 
years. For more specific suggestions pertaining to storage of NGS technology data, 
ACMG guidelines recommend that the genomics laboratory consider a minimum of 2-
year storage of a digital file type that would allow regeneration of the primary results 
as well as reanalysis with improved analytic pipelines. In terms of storage of raw data, 
it is important to clarify what types of data resulting from WGS could be stored by the 
laboratories in the clinical and research settings. Data analysis based on WGS 
generates three file types: (i) FASTQ, which contains raw sequences with 
corresponding quality scores; (ii) BAM (binary alignment/map), generated by mapping 
of raw sequences to the human genome reference; and (iii) the VCF (variant call 
format) file, which contains a list of sequence variants, sorted by genomic position, at 
which the individual differs from the reference genome. As Evans and colleagues note, 
“[m]any laboratories produce an annotated VCF with numerous details (such as 




interpretation of each variant. This information, in part, is used to generate the final 
report for clinicians and patients.”100  
 
 Current ACMG clinical laboratory standards for next-generation sequencing 
assert: “Laboratories should make explicit in their policies which file types and what 
length of time each type will be retained, and the data retention policy must be in 
accordance with local, state, and federal requirements.”101They go on to recommend 
retention of the VCF and final clinical test report “for as long as possible, given the 
likelihood of a future request for reinterpretation of variant significance.”   Currently, 
some clinical laboratories do describe their policies relating to storage of raw data in 
their consent forms, informing the patients about the availability of DNA sequence data 
for reanalysis and storage of DNA sequence data for various purposes such as test 
validation or for research. In contrast, some laboratories only indicate the possibility of 
future policies to incorporate genetic sequence data to permanent medical records.102 
With regard to retention of files, the current practices indicate that storing VCF files 
and, possibly, BAM and FASTQ files by laboratories is necessary.  
 
Long-term retention and return of raw genomic data policies may fuel a number of 
concerns. In terms of the retention, potential unintentional data uses resulting from 
long-term storage of raw data in patients’ medical records (for examples by insurance 
companies or employers) have been underlined as a potential concern. ESHG 
recommendations, for instance, highlight the potential informational risks that could 
result from long-term storage of raw genomic data, and recommend that the potential 
implications of access by insurance companies and employers should be addressed.51  
Similarly, a report by PHG Foundation in the UK summarizes the main points: “It could 
be argued that not storing individual genomic data and re-analysing it in this way would 
present an enormous missed opportunity to improve both individual and population 
health. However, storing entire or minimal genome sequences for individual patients 
would require the use of electronic health records (at least in part), which has major 
practical and ethical implications. In addition, future technological developments may 
result in a substantial improvement in the quality of sequencing and genome 
assembly, and thus make re-sequencing an individual (as required) a better option.”103 
In response, storage of raw data privately and outside the patients’ medical records 
has been suggested as a potential solution. A recent example is MIDATA, a non-profit 
cooperative that offers patients private storage for a wide range of health and personal 
data, and allows patients to decide who should have access to the data and for which 
purposes.  
 
In the context of raw data returning policies of WGS research projects, Thorougood 
and colleagues recently concluded that the current practices of ten projects show: 
“Data types and formats may differ depending on the context, sequencing platform, 
analysis pipelines, and evolution of common file formats. The examples of genomic 
data formats currently provided to participants include reduced BAM, VCF, and 
FASTQ.”104 Return of genomic data directly to patents and research subjects also 
raises the potential for individuals to use of third party websites to seek their own 
interpretation of the genomic data, which has been perceived by some experts as 
concerning. Previous studies have shown that individuals may upload their data on 
online platforms that provide services for interpretation of raw data, such as openSNP, 
Promethease, GEDMatch, and Genome Mate Pro. The features of such websites vary, 




As with direct-to-consumer genetic testing services such as 23&Me, and online 
wellness genomics platforms, concerns have been raised about returning significant 
medical information to the individuals without the support and counselling provided by 
qualified health care professionals.106 These questions about how much support 
individuals should receive from their healthcare providers in order to interpret the raw 
data persist.  
 
4) Economic dimensions of returning secondary findings from genomics in 
clinical routine care 
  Although there are many potential opportunities from using NGS 
technologies, including WES and WGS, there is considerable uncertainty regarding 
whether they will deliver anticipated improvements in patient health. The health 
economic case for these technologies requires that their value to health care providers 
can be demonstrated.107 This requires an assessment of their costs and benefits 
compared to other technologies (standard practice care), the implications for health 
care systems and an understanding of patient and other stakeholder views. Whilst the 
latter is obviously important in its own right, if fewer people undergo sequencing, this 
could mean that insufficient samples are sequenced in bulk, which would increase 
costs and reduce the likelihood that sequencing will be cost-effective. There is some 
evidence that applying NGS in clinical practice might improve the diagnosis and (in 
some cases) treatment of genetic disease. However, demand is increasing for 
evidence on the cost-effectiveness of these technologies compared to current practice 
to ensure that the technologies are not merely an expensive add-on to patient care.108  
 
 A recent systematic review identified only 36 papers that reported economic 
evaluations, cost studies or outcome studies related to WES and WGS. Most provided 
little detail on their study methods and generally did not consider the clinical or 
economic implications for patients after receiving a diagnosis.109 Although these 
studies looked at sequencing in several genetic conditions, they most commonly 
examined neurological and neurodevelopmental disorders. Study sample sizes varied 
from a single child to 2,000 patients, with most studies having small sample sizes. 
There were large ranges in cost estimates for a single test, from $555 to $5,169 for 
WES and from $1,906 to $24,810 for WGS. The review concluded there was an urgent 
need for studies that carefully evaluate the costs, effectiveness, and cost-effectiveness 
of NGS technologies.  
 
 Effectively responding to secondary findings could incur significant initial 
financial costs, but could reduce morbidity, mortality, and overall costs, if this 
information helps to identify diseases at an earlier stage. Whilst there is limited health 
economic evidence on use of NGS generally, there is even less information on specific 
components of NGS, such as the use of secondary findings, especially with respect to 
cost-effectiveness and stakeholder preferences. A number of health economic 
analyses are, however, worth highlighting, including an economic decision model by 
Bennette et al110 and a stakeholder survey by Regier et al111.   
 
 Bennette and colleagues evaluated the clinical and economic impact of 
returning the ACMG-recommended secondary finding results.110 They developed a 
decision model to estimate the likely quality-adjusted life years (QALYs) and lifetime 
costs associated with returning these findings in three hypothetical cohorts of 10,000 




inherited heart diseases), patients with colorectal cancer or polyposis, and ‘healthy’ 
individuals undergoing testing because family members have genomic risk factors (or 
family history indicates a specific disease risk). The authors concluded that returning 
secondary findings to patients could be cost-effective for certain populations, with 
QALYs increasing in all three groups. However, screening of generally healthy 
individuals was not cost-effective based on their calculations, unless genomic 
sequencing costs are less than $500 per patient. In the current climate, this is still an 
ambitious price for sequencing the genome of one patient. In fact, sequencing 
currently costs over $2,500 per patient if it is conducted within individual laboratories, 
as opposed to being centralised and at scale.112 
 
 From an economics perspective, personal utility is essentially the ‘well-being’ 
people experience from choosing a particular health care service. A Canadian study 
by Regier et al attempted to estimate the personal utility derived from the reporting of 
secondary findings.111 They used a survey method called a discrete choice experiment 
to evaluate participants’ personal utility for reporting secondary findings. A discrete-
choice experiment is used commonly in economics (not just health economics) and 
market research to gather preferences from stakeholders for different attributes of a 
good or a service, which gives an indication of how much an individual values that 
good/service. By breaking down a good/service into its various attributes 
(characteristics), each having its own corresponding levels, survey participants are 
able to trade off different attributes against each other, and researchers can then see 
which attributes are considered the most or least important to individuals and 
understand whether a particular good/service is preferred.113 Regier et al used five 
attributes in their discrete choice experiment investigating preferences for returning 
secondary findings: disease penetrance, disease treatability, disease severity, carrier 
status and cost, which were described in the survey in the context of hypothetical 
diseases.111 The survey participants were 1200 members of the general Canadian 
public.  
 
 Participants indicated that they valued receiving information about high-
penetrance disorders (larger proportion of individuals with the mutation who have 
clinical symptoms) but did not value receiving information on low-penetrance disorders 
(smaller proportion of individuals with the mutation who have clinical symptoms). The 
average willingness to pay to receive secondary findings was $445 in a scenario where 
clinicians returned information about high-penetrance, medically treatable disorders, 
but only 66% of participants indicated that they would choose to receive information in 
that scenario. On average, participants placed importance on having a choice about 
what type of findings they would receive, including receiving information about high-
penetrance, treatable disorders or receipt of information about high-penetrance 
disorders with or without available treatment. The predicted uptake of that scenario 
was 76%. Although most of the people completing the survey valued receiving 
information on secondary findings, personal utility depended on the type of finding, 
and not all participants wanted to receive this information, irrespective of the potential 
health implications.111 These survey findings are important because they suggest that a 
one size fits all approach to reporting secondary findings might not be appropriate. 
This evidence is interesting given the discussion earlier in the chapter about the use 
of wellness genomics, given that survey respondents were more likely to value the use 





 The limited number of health economic assessments on secondary findings 
have generally used health economic decision models or surveys (rather than patient 
level data) to examine likely costs and effects of returning information on secondary 
findings to patients. To fully understand the economic value of returning these findings, 
it will be important in the future to make use of the wealth of clinical and economic 
information being generated within large sequencing programmes such as the UK 
100,000 Genomes Project and large centralised biobanks. These initiatives are 
routinely collecting resource use data, which could be used to assess the cost-
effectiveness of using secondary findings in routine health care. 
 
5) Discussion and conclusions 
 This chapter has demonstrated that when it comes to a pre-defined list of 
secondary findings to be routinely examined as part of genomics in clinical care, there 
is considerable variation between countries, and between jurisdictions within 
federated countries such as Australia and Canada. There are different approaches 
and considerations at play in different settings such as paediatric and adult clinical 
care, disease-focused or wellness genomics, and even in terms of which technique –
WGS, WES, multiple panel testing, et cetera - should be employed. The evidence for 
the economic cost effectiveness of returning particular sets of secondary or additional 
findings is equivocal and will require further studies. Much the same can be said of the 
current study of patient preferences across jurisdictions, conditions, in paediatric 
versus adult cohorts and in terms of whether attitudes to receiving secondary or 
additional findings vary according to other socio-demographic characteristics.  
 
 A number of theories and models have been developed to account for 
successful or unsuccessful adoption of novel health technologies. These include the 
field of implementation science114, normalisation process theory,115 and the notion of 
an ‘adoption space’ where emerging technologies gain an identity as a ‘cutting edge’, 
‘life saving’ or ‘complicated’ and ‘expensive’ that influences whether and where they 
are seen as worth adopting by hospital managers and other professional groups.116 
Although these concepts are all distinct they have some features in common. Firstly, 
they are rarely systematically applied to clinical genomics. Secondly, they all 
emphasise, in different ways, that any new technology will be operating in an existing 
environment of organisational frameworks, professional roles and practices, legal 
requirements and responsibilities, physical and technological infrastructure, social and 
cultural norms, expectations and values, and political and economic structures and 
imperatives. While a machine may ‘work’ according to the way it is designed, making 
it ‘workable’ –that is making it practically usable in a real world context –also requires 
embedding the technology in this multi-layered existing environment. This may mean 
adapting both the environment and some features of the technology: “technologies will 
always need skilled human work, inter-sectoral negotiation and a social infrastructure 
to ensure that they ‘work’”.117 
 
 The case of secondary findings in genomics exemplifies this translational work. 
As discussed above, secondary findings can be understood as a strategy to create a 
standard of care- an ethically and professionally acceptable way of dealing with the 
‘overspill’ of unintended genomic results- that allows clinical implementation of NGS 
technologies to proceed. Secondary findings effect a separation between genomic 
variants whose significance is known and agreed to be serious and actionable, and 




intended to enable action, by providing a normative guide on how to use the 
technology appropriately. The fact that the ACMG guidelines have had an impact on 
debates far beyond the borders of the USA shows how critical resolving this tension 
has been in facilitating translation and making clinical genomics ‘workable’. Equally, 
the fact that several jurisdictions are using, or trialing their own lists of secondary 
findings, different from those specified by the ACMG, demonstrates that while the idea 
is extremely useful, clear criteria for demarcating clinically actionable from not (yet) 
actionable variants are far from universally agreed. Genomics England, for example 
employs a significantly shorter list of secondary findings compared to the ACMG list 
while the French tradition supports looking for and returning a greater number of 
variants.  The idea of secondary findings is therefore not a simple binary proposition 
– return them or do not- it is also a question of how which additional findings might be 
returned and how this should best be achieved.  
 
 Beyond the different criteria for clinical actionability, any attempt to implement 
return of secondary or additional findings also requires addressing a plethora of related 
‘how’ issues: whether to implement ‘opt-out’ mechanisms recognizing patients’ right 
‘not to know’ and/or ‘opt-in’ mechanisms operationalizing the corollary ‘right to know’; 
whether to provide pre-test genetic counselling and/or post-test counselling in all 
cases or only some; whether to return all findings in one go, or separate return of the 
primary result of genomic testing by leaving return of secondary or additional findings 
to a later date; what recontact options should be in place, especially for paediatric 
patients who may wish to consent to receiving additional findings on reaching the legal 
age of capacity; whether patients can access –or have a right to access- their ‘raw’ 
sequence data files and/or transfer them to third party analysis services; and working 
out whether genomic testing is being rolled out as an aid to primary diagnosis (as in 
paediatric rare disease), patient stratification as part of a precision medicine initiative  
(as in refining cancer diagnoses), or as a screening tool (as with the MyCode 
Community Health Initiative, and the proposals for neonatal and prenatal screening 
programs)?  
 
 The feasibility of each of these different options will depend a lot on the existing 
environment. Are enough genetic counsellors available to provide pre and post-test 
counselling in all cases, are recontact mechanisms in place or do they have to be 
created, what do existing legal instruments say about the duty of care or of 
confidentiality, what budget is available for different activities et cetera? Collecting and 
supplementing the datasets needed to make reliable correlations between genotype 
and phenotype also takes clinical genomics into the realms of data transfer between 
institutions, across borders, and in some cases between public and private sectors. 
This requires considerations of privacy, data protection, data ownership, and 
intellectual property.118,119 That these are not simple requirements to negotiate is 
attested to by the ongoing work of groups like the Global Alliance for Genomics and 
Health (Ga4GH) which attempts to produce harmonised international standards to 
enable legal sharing of genomic data.120 The heterogeneity of existing systems and 
their differing capacity to engage with international data flows and regulations 
accounts for a further chunk of the variability in the way secondary or additional 
findings are managed in practice .  
 
 Translation of genomics is given an additional layer of complexity because it 




learning healthcare system is that new technologies can be translated by using them 
to provide care in the clinical context while at the same time using the data from their 
clinical usage to update and improve the way they are used. In the case of genomics 
this means integrating genomic data into clinical care while utilising genomic data 
collected in the clinical context to update the datasets used to correlate genomic and 
phenotypic data. It also means collecting evidence for the cost-effectiveness of using 
genomic data and returning different kinds of findings through the process of rolling 
these services out into clinical care. In essence this is a model of ongoing ‘learning by 
doing’. A learning healthcare model represents a significant divergence from the clear 
separation of research and care that characterises traditional healthcare systems. The 
challenge of making clinical decisions on an evidence base that is not only subject to 
change but where the decision to participate actively affects that evidence base raises 
a number of ethical and organisational challenges, especially with regards to collecting 
meaningful consent from participants about what returning results is likely to mean 
(and that this meaning is subject to change and may necessitate future recontact).70,122 
This is particularly the case with the statistical risk associated with a particular variant 
in an asymptomatic individual, which therefore has direct relevance to secondary and 
additional findings.  
 
 Ultimately, most jurisdictions described here have adopted some form of 
exploratory implementation of clinical genomics, dealing with secondary or additional 
findings through smaller evaluative studies, or flagship projects that remain separate 
from mainstream healthcare until sufficient evidence can be collected to inform further 
development. In this regard, it is not necessarily problematic that different territories 
approach things in a different manner. Although regulatory harmonisation is often 
eulogised, trying different strategies in different locations affords an opportunity for 
organisations to learn from a wider range of experience, if- crucially- mechanisms are 
put in place to report on what works and what is unsuccessful in different locations 
and to share this information among relevant stakeholders.123This is a different kind of 
organisational learning from that envisioned by the learning healthcare system, but 
nonetheless may be equally relevant to clinical genomics.  
 
  A further complication is the rise of genomics services provided direct to 
consumer, or direct to provider (including private providers) which mix analysis 
relevant to clinical care with findings relating, or pertaining to relate to nutrition, 
wellbeing, ancestry, diet, exercise, and other lifestyle factors.   As these genomic 
services can be presented as lifestyle, education or entertainment products, and are 
often marketed and sold online, they tend to escape many of the challenges of 
implementing clinical genomics in practice. Although desirable from a strictly economic 
standpoint, this is less desirable from a health protection perspective as these services 
may avoid having to make responsible decisions about return of secondary of 
additional findings and all the implementation measures that accompany them. There 
is seldom any provision of genetic counselling before or after testing, and policies on 
paediatric testing, recontact, ownership of genomic data and other aspects may be 
lacking or out of step with prevailing ethical and regulatory consensus. The 
development of coherent and responsible national and international principles for 
managing secondary and additional findings must therefore also consider those uses 
of genomics that fall outside the purview of traditional clinical services. There is a 
strong argument that, as ideas of agreed best practice for testing, evaluating and 




coalesce out of the current, exploratory translational research programmes, they 
should also shape the appropriate standards (e.g. provision of genetic counselling) for 
online and private sector genomics services whether these present themselves as 
health-related, educational or otherwise. 
 
6) References  
 
1. Middleton A, Morley KI, Bragin E, Firth HV, Hurles ME, Wright CF et al. Attitudes of 
nearly 7000 health professionals, genomic researchers and publics toward the return 
of incidental results from sequencing research. Eur J Hum Genet. 2016; 24: 21-29. 
 
2. Tan N, Amendola LM, O’Daniel JM, Burt A, Horike-Pyne MJ, Boshe L., et al. Is 
“incidental finding” the best term? A study of patient’s preferences. Genetics in 
Medicine. 2017; 19:176-181. 
 
3. Hall M, Bobinski MA, Orentlicher D. Medical liability and treatment relationships. 2nd 
Edition. New York, NY: Aspen Publishers; 2008.  
 
4. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL et al. ACMG 
Recommendations for Reporting Incidental Findings in Clinical Exome and Genome 
Sequencing. Genetics in Medicine. 2013; 15 (7): 565-574. 
 
5. Burke W, Antommaria AH, Bennet R, Botkin J, Clayton EW, Henderson GE, et al. 
Recommendations for returning genomic incidental findings? We need to talk! Genet 
Med 2013; 15: 855-859. 
 
6. Wolf SM, Annas GJ, Elias S. Patient Autonomy and Incidental Findings in Clinical 
Genomics. Science. 2013; 340 (6136): 1049-1050.  
 
7. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. 
Recommendations for reporting of secondary findings in clinical exome and genome 
sequencing, 2016 update (ACMG SF v2. 0): A policy statement of the American 
College of Medical Genetics and Genomics. Genet Med. 2017; 19: 249-255. 
 
8. American College of Medical Genetics and Genomics. ACMG Updates 
Recommendation on “Opt Out” for Genome Sequencing Return of Results. 
https://www.acmg.net/docs/Release_ACMGUpdatesRecommendations_final.pdf. 
Accessed July 26, 2018. 
 
9. Fowler SA, Saunders CJ, Hoffman MA. Variation among consent forms for clinical 
whole exome sequencing. J Genet Couns. 2018; 27(1):104-114. 
 
10. Andrews M. What if your doctor offered genetic testing as a way to keep you 




July 26, 2018. 
 
11. Geisinger Health. MyCode Conditions 2016. https://www.geisinger.org/precision-





12. Berg JS, Foreman AK, O'Daniel JM, Booker JK, Boshe L, Carey T, et al. A semi-
quantitative metric for evaluating clinical actionability of incidental or secondary 
findings from genome-scale sequencing. Genet Med 2016; 18: 467-475. 
 
13. Collins FS, Varmus H (2015) A new initiative on precision medicine. NEJM 372:793–
795. 
 
14. Genomics Working Group of the All of Us Research Program. Considerations toward 
a comprehensive genomics strategy. 
https://allofus.nih.gov/sites/default/files/gwg_final_report.pdf.  Accessed August 20, 
2018 
 
15. National Academies of Sciences, Engineering, and Medicine. 2018. Returning 
Individual Research Results to Participants: Guidance for a New Research 
Paradigm. Washington, DC: The National Academies Press. doi: 
https://doi.org/10.17226/ 
 
16. Genomics England. The 100,000 Genomes Project. 
https://www.genomicsengland.co.uk/the-100000-genomes-project/. Accessed 
October 28 2018  
 
17. Godfrey K. Genetics white paper heralds “a revolution in health care.” BMJ 2003 
32(7404):1413.  
 
18. The Royal College of Radiologists. Standards for interpretation and reporting of 
imaging investigations Second edition. Clin Radiol. 2018;(March). 
https://www.rcr.ac.uk/system/files/publication/field_publication_files/bfcr181_standard
s_for_interpretation_reporting.pdf. Accessed February 21st 2019. 
 
19. Mitchell C, Ploem C, Chico V, Ormondroyd E, Hall A, Wallace S, et al. Exploring the 
potential duty of care in clinical genomics under UK law. Med Law Int. 2017;17(3): 
158–82.  
 
20. Hehir-Kwa JY, Claustres M, Hastings RJ, Van Ravenswaaij-Arts C, Christenhusz G, 
Genuardi M, et al. Towards a European consensus for reporting incidental findings 
during clinical NGS testing. Eur J Hum Genet. 2015;23(12):1601–6.  
 
21. Hall A, Hallowell N, Zimmern R. Managing incidental and pertinent findings from 
WGS in the 100,000 Genome Project. PHG Foundation. 2013. ISBN 978-1-907198-
12-0.  
 
22. Wright CF, Middleton A, Burton H, Cunningham F, Humphries SE, Hurst J, et al. 
Policy challenges of clinical genome sequencing. BMJ. 2013;347(nov22 3): f6845–
f6845. doi: https://doi.org/10.1136/bmj.f6845 
 
23. Abul-Husn NS, Manickam K, Jones LK, Wright EA, Hartzel DN, Gonzaga-Jauregui C, 
et al. Genetic identification of familial hypercholesterolemia within a single U.S. 
health care system. Science. 2016;354(6319). doi: 10.1126/science.aaf7000. 
 
24. Wolf SM, Elias S. NIH Public Access. 2013;340(6136):1049–50.  
 
25. Ormondroyd E, Mackley M, Blair E, Craft J, Knight JC, Taylor J et al. “Not pathogenic 
until proven otherwise”: perspectives of UK clinical genomics professionals towards 
secondary findings in context of a Genomic Medicine Multidisciplinary Team and the 





26. Davies S. Annual Report of the Chief Medical Officer 2016 - Generation Genome. 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/63104
3/CMO_annual_report_generation_genome.pdf. Accessed October 28, 2018. 
 
27. NHS Science and Technology Committee. Genomics and genome editing in the 
NHS. 
https://publications.parliament.uk/pa/cm201719/cmselect/cmsctech/349/34902.htm. 
Accessed October 28, 2018. 
 
28. Hill S. The genomic revolution – its future. https://www.england.nhs.uk/blog/genomic-
revolution/. Accessed February 21st 2019. 
 
29. National Health and Medical Research Council. Principles for the translation of 
‘omics’–  based tests from discovery to health care. Canberra: National Health and 
Medical Research Council; 2015. 
 
30. Human Genetics Society Australasia.  HGSA Commentary on ACMG 
Recommendations. https://www.hgsa.org.au/hgsanews/hgsa-commentary-on-acmg-
recommendations. Accessed 27 September, 2018. 
 
31. Royal College of Pathologists of Australia. Massively Parallel Sequencing 
Implementation Guidelines.  https://www.rcpa.edu.au/Library/Practising-
Pathology/RCPA-Genetic-Testing/MAPSIG Accessed 27 September, 2018. 
 
32. Gaff CL, Winship M, Forrest IM, Hansen SP, Clark D, Waring JM, et al. Preparing for 
genomic medicine: a real world demonstration of health system change. Genomic 
Medicine. 2017; 2(1), 16. doi:10.1038/s41525-017-0017-4 
 
33. Gaff C. Unpublished research data. 
 
34. Australian Government Department of Health. Health Technology Assessment for 
reimbursement. 
http://www.health.gov.au/internet/hta/publishing.nsf/content/reimbursement-1. 
Accessed 21st February 2019. 
 
35. Ackerman SL, Koenig BA. Understanding variations in secondary findings reporting 
practices across U.S. genome sequencing laboratories. AJOB Empirical Bioethics. 
2017; 9(1): 48-57, doi: 10.1080/23294515.2017.1405095  
 
36. Martyn M, Kanga-Parabia A, Lynch E, James PA, et al.  A novel approach to offering 
additional findings- testing a two-step approach in the healthcare system. J Genet 
Couns. 2019; doi: 10.1002/jgc4.1102. [Epub ahead of print]. 
 
37. Bergner AL, Bollinger J, Raraigh KS, Tichnell C, Murray B, Blout CL, et al. Informed 
consent for exome sequencing research in families with genetic disease: the 
emerging issue of incidental findings. Am J Med Genet Part A. 2014; 164A: 2745–
2752.  
 
38. Bernhardt BA, Roche MI, Perry DL, Scollon SR, Tomlinson AN, Skinner D. 
Experiences with obtaining informed consent for genomic sequencing. Am J Med 





39. Downie L, Halliday J, Burt R, Lunke S, Lynch E, Martyn M, et al. A protocol for whole-
exome sequencing in newborns with congenital deafness: a prospective population-
based cohort. BMJ Paediatrics Open. 2017; doi:10.1136/bmjpo-2017-000119. 
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